<?xml version='1.0'?>
<!DOCTYPE art SYSTEM 'http://www.biomedcentral.com/xml/article.dtd'>
<art>
<ui>1756-9966-30-95</ui>
<ji>1756-9966</ji>
<fm>
<dochead>Review</dochead>
<bibl>
<title><p>The mechanisms by which polyamines accelerate tumor spread</p></title>
<aug>
<au ca="yes" id="A1"><snm>Soda</snm><fnm>Kuniyasu</fnm><insr iid="I1"/><email>soda@omiya.jichi.ac.jp</email></au>
</aug>
<insg>
<ins id="I1"><p>Department of Surgery and Cardiovascular Research Institute, Saitama Medical Center, Jichi Medical University, 1-847 Amanuma, Omiya, Saitama-city, Saitama (330-0834), Japan</p></ins>
</insg>
<source>Journal of Experimental &amp; Clinical Cancer Research</source>
<issn>1756-9966</issn>
<pubdate>2011</pubdate>
<volume>30</volume>
<issue>1</issue>
<fpage>95</fpage>
<url>http://www.jeccr.com/content/30/1/95</url>
<xrefbib><pubidlist><pubid idtype="doi">10.1186/1756-9966-30-95</pubid><pubid idtype="pmpid">21988863</pubid></pubidlist></xrefbib></bibl>
<history><rec><date><day>15</day><month>7</month><year>2011</year></date></rec><acc><date><day>11</day><month>10</month><year>2011</year></date></acc><pub><date><day>11</day><month>10</month><year>2011</year></date></pub></history><cpyrt><year>2011</year><collab>Soda; licensee BioMed Central Ltd.</collab><note>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<url>http://creativecommons.org/licenses/by/2.0</url>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</note></cpyrt>
<kwdg><kwd>Polyamine</kwd><kwd>metastasis</kwd><kwd>spermine</kwd><kwd>spermidine</kwd><kwd>LAK</kwd><kwd>LFA-1</kwd></kwdg>
<abs>
<sec><st><p>Abstract</p></st>
<p>Increased polyamine concentrations in the blood and urine of cancer patients reflect the enhanced levels of polyamine synthesis in cancer tissues arising from increased activity of enzymes responsible for polyamine synthesis. In addition to their <it>de novo </it>polyamine synthesis, cells can take up polyamines from extracellular sources, such as cancer tissues, food, and intestinal microbiota. Because polyamines are indispensable for cell growth, increased polyamine availability enhances cell growth. However, the malignant potential of cancer is determined by its capability to invade to surrounding tissues and metastasize to distant organs. The mechanisms by which increased polyamine levels enhance the malignant potential of cancer cells and decrease anti-tumor immunity are reviewed. Cancer cells with a greater capability to synthesize polyamines are associated with increased production of proteinases, such as serine proteinase, matrix metalloproteinases, cathepsins, and plasminogen activator, which can degrade surrounding tissues. Although cancer tissues produce vascular growth factors, their deregulated growth induces hypoxia, which in turn enhances polyamine uptake by cancer cells to further augment cell migration and suppress CD44 expression. Increased polyamine uptake by immune cells also results in reduced cytokine production needed for anti-tumor activities and decreases expression of adhesion molecules involved in anti-tumor immunity, such as CD11a and CD56. Immune cells in an environment with increased polyamine levels lose anti-tumor immune functions, such as lymphokine activated killer activities. Recent investigations revealed that increased polyamine availability enhances the capability of cancer cells to invade and metastasize to new tissues while diminishing immune cells' anti-tumor immune functions.</p>
</sec>
</abs>
</fm>
<bdy>
<sec><st><p>1. Introduction</p></st>
<p>Polyamines, which include spermidine and spermine, are polycations with three or four amine groups. Almost all cells can produce polyamines, but their production is especially high in rapidly growing cells. Polyamine concentrations are often increased in the blood and urine of cancer patients, and these increased levels have been shown to correlate with poor prognosis <abbrgrp><abbr bid="B1">1</abbr></abbrgrp>. The increased blood and urinary polyamine levels are attributable to increased polyamine synthesis by cancer cells, since these increases can be abolished by complete eradication of tumors by surgery or radio-chemotherapy <abbrgrp><abbr bid="B2">2</abbr><abbr bid="B3">3</abbr><abbr bid="B4">4</abbr><abbr bid="B5">5</abbr></abbrgrp>. The capacity of cancer tissue to produce abundant polyamines likely contributes to cancer cells' enhanced growth rates because polyamines are indispensable for cellular growth, which may at least partially explain why cancer patients with increased polyamine levels have a poorer prognosis <abbrgrp><abbr bid="B4">4</abbr><abbr bid="B5">5</abbr><abbr bid="B6">6</abbr><abbr bid="B7">7</abbr><abbr bid="B8">8</abbr><abbr bid="B9">9</abbr></abbrgrp>. However, an important factor that determines the malignant potential of cancer cells is the capability of cells to invade to surrounding tissues and to metastasize to distant organs. Therefore, it is important to understand the role of polyamines in cancer invasion and metastasis. In this review, recent experimental results from our and other groups are discussed.</p>
</sec>
<sec><st><p>2. What are polyamines?</p></st>
<p>The natural polyamines, spermidine, and spermine, are found in almost every living cell at high micromolar to low millimolar quantities <abbrgrp><abbr bid="B10">10</abbr></abbrgrp>. Polyamines are synthesized from arginine and s-adenosylmethionine with arginase converting arginine to ornithine, and ornithine decarboxylase (ODC) catalyzing ornithine decarboxylation to form putrescine, a polyamine precursor containing two amine groups (Figure <figr fid="F1">1</figr>). Polyamines are involved in diverse functions involved in cell growth and differentiation, such as DNA synthesis and stability, regulation of transcription, ion channel regulation, and protein phosphorylation <abbrgrp><abbr bid="B11">11</abbr><abbr bid="B12">12</abbr><abbr bid="B13">13</abbr><abbr bid="B14">14</abbr></abbrgrp>.</p>
<fig id="F1"><title><p>Figure 1</p></title><caption><p>Polyamine biosynthesis, degradation, and transmembrane transport</p></caption><text>
   <p><b>Polyamine biosynthesis, degradation, and transmembrane transport</b>. The polyamines spermine and spermidine are synthesized from arginine. Arginase converts arginine to ornithine, and ornithine decarboxylase (ODC) catalyzes decarboxylation of ornithine to form putrescine, a polyamine precursor containing two amine groups. ODC, a rate-limiting enzyme with a short half-life, is inhibited by antizyme, and antizyme is inhibited by an antizyme inhibitor. S-adenosylmethionine decarboxylase (AdoMetDC) is the second rate-limiting enzyme in polyamine synthesis and is involved in the decarboxylation of S-adenosylmethionine. Spermidine synthetase and spermine synthase are constitutively expressed aminopropyltransferases that catalyze the transfer of the aminopropyl group from decarboxylated S-adenosylmethionine to putrescine and spermidine to form spermidine and spermine, respectively. Polyamine degradation is achieved by spermine/spermidine N<sup>1</sup>-acetyltransferase (SSAT) and N<sup>1</sup>-acetylpolyamine oxidase (APAO). In addition, spermine oxidase (SMO) specifically oxidizes spermine. Polyamines are transported across the membrane transmembrane by the polyamine transporter.</p>
</text><graphic file="1756-9966-30-95-1" hint_layout="single"/></fig>
<p>Intracellular spermine and spermidine are degraded by spermidine/spermine N<sup>1</sup>-acetyltransferase (SSAT) and N<sup>1</sup>-acetylpolyamine oxidase (APAO). SSAT, a highly inducible enzyme, catalyzes the transfer of an acetyl group from acetyl-coenzyme A to the aminopropyl moiety of spermine and spermidine. APAO was previously described as polyamine oxidase but it preferentially catalyzes the oxidation of the <it>N</it><sup>1</sup>-acetylspermine and <it>N</it><sup>1</sup>-acetylspermidine produced by SSAT activity. This oxidation results in the production of H<sub>2</sub>O<sub>2</sub>, 3-acetoaminopropanal, and putrescine or spermidine (Spd), depending on the initial substrate <abbrgrp><abbr bid="B15">15</abbr><abbr bid="B16">16</abbr><abbr bid="B17">17</abbr></abbrgrp>. Mammalian spermine oxidase (SMO) is an inducible enzyme that specifically oxidizes spermine, with the production of H<sub>2</sub>O<sub>2</sub>, 3-aminopropanal (3AP) and spermidine <abbrgrp><abbr bid="B16">16</abbr><abbr bid="B17">17</abbr></abbrgrp>.</p>
<p>In addition to <it>de novo </it>synthesis and degradation, cellular polyamine concentrations are also regulated by transmembrane transport where cells take up polyamines from their surroundings or export them to the extracellular space (Figure <figr fid="F1">1</figr>).</p>
</sec>
<sec><st><p>3. Polyamines and cancer</p></st>
<p>Polyamine biosynthesis is up-regulated in actively growing cells, including cancer cells <abbrgrp><abbr bid="B10">10</abbr><abbr bid="B18">18</abbr><abbr bid="B19">19</abbr></abbrgrp>, therefore polyamine concentration as well as gene expression and activity of enzymes involved in polyamine biosynthesis, especially ODC, are higher in cancer tissues than in normal surrounding tissues <abbrgrp><abbr bid="B8">8</abbr><abbr bid="B20">20</abbr><abbr bid="B21">21</abbr><abbr bid="B22">22</abbr><abbr bid="B23">23</abbr><abbr bid="B24">24</abbr><abbr bid="B25">25</abbr></abbrgrp>.</p>
<p>Numerous reports have shown that both blood and urine polyamine concentrations are often increased in cancer patients <abbrgrp><abbr bid="B4">4</abbr><abbr bid="B5">5</abbr><abbr bid="B7">7</abbr><abbr bid="B8">8</abbr><abbr bid="B10">10</abbr></abbrgrp>. A close correlation between blood polyamine levels and the amount of urinary polyamines has also been found in cancer patients <abbrgrp><abbr bid="B1">1</abbr></abbrgrp>. Moreover, these levels decrease after tumor eradication and increase after relapse <abbrgrp><abbr bid="B2">2</abbr><abbr bid="B3">3</abbr><abbr bid="B4">4</abbr><abbr bid="B5">5</abbr><abbr bid="B23">23</abbr></abbrgrp>, indicating that polyamines synthesized by cancer tissues are transferred to the blood circulation and kidney, where they are excreted into the urine <abbrgrp><abbr bid="B26">26</abbr></abbrgrp>.</p>
<p>Polyamines are also produced in other parts of the body and can be transported to various organs and tissues such as the intestinal lumen where polyamines are absorbed quickly to increase portal vein polyamine concentrations <abbrgrp><abbr bid="B27">27</abbr></abbrgrp>. The majority of spermine and spermidine in the intestinal lumen is absorbed in their original forms because there is no apparent enzymatic activity present to catalyze their degradation <abbrgrp><abbr bid="B28">28</abbr></abbrgrp>. Polyamines absorbed by the intestinal lumen are distributed to almost all organs and tissues in the body <abbrgrp><abbr bid="B29">29</abbr></abbrgrp> as demonstrated by the increased blood polyamine levels in animals and humans produced in response to continuous enhanced polyamine intake for six and two months, respectively <abbrgrp><abbr bid="B30">30</abbr><abbr bid="B31">31</abbr></abbrgrp>. However, short-term increased polyamine intake failed to produce such increases <abbrgrp><abbr bid="B30">30</abbr><abbr bid="B31">31</abbr><abbr bid="B32">32</abbr></abbrgrp>, possibly because of the homeostasis that inhibits acute changes in intracellular polyamine concentration. On the other hand, reductions in blood polyamine concentration were not achieved only by restricting oral polyamine intake. As such, at least two sources of intestinal polyamines are postulated: foods and intestinal microbiota. Decrease in blood polyamine levels can be successfully achieved by eliminating intestinal microbiota in addition to restricting food polyamines <abbrgrp><abbr bid="B33">33</abbr></abbrgrp>. Taken together, these results indicate that polyamines are not only produced by cancer tissues but are also supplied from the intestinal lumen and together appear to influence polyamine levels in the body of cancer patients.</p>
<sec><st><p>3. Polyamines in the body</p></st>
<p>In vitro experiments showed that cultured cells take up polyamines from their surroundings <abbrgrp><abbr bid="B34">34</abbr><abbr bid="B35">35</abbr></abbrgrp>. In blood circulation, the majority of polyamines are contained in blood cells, especially in red and white blood cells, and therefore increases in blood polyamine concentration indicate concurrent increases in polyamine levels in blood cells <abbrgrp><abbr bid="B36">36</abbr></abbrgrp>. Similarly, intracellular polyamine concentrations in cells of otherwise normal tissues and organs in cancer patients can be increased <abbrgrp><abbr bid="B37">37</abbr></abbrgrp>. One examination showed that spermidine and spermine levels are increased in the normal colon mucosa of cancer patients compared to the normal colon mucosa from patients without cancer <abbrgrp><abbr bid="B37">37</abbr></abbrgrp>, although another study was unable to detect these differences <abbrgrp><abbr bid="B38">38</abbr></abbrgrp>. Given that polyamine concentrations are increased in the blood cells of cancer patients and numerous blood cells with increased polyamine concentrations exist in normal tissues, the polyamine concentration in normal tissues of cancer patients with increased blood polyamine levels might also be increased. In addition, orally administered radiolabeled polyamines have been shown to be immediately distributed to almost all organs and tissues <abbrgrp><abbr bid="B29">29</abbr><abbr bid="B39">39</abbr><abbr bid="B40">40</abbr></abbrgrp>.</p>
<p>Polyamine concentrations in the blood vary considerably among healthy individuals such that concentrations are not necessarily higher in cancer patients than in otherwise normal subjects <abbrgrp><abbr bid="B41">41</abbr><abbr bid="B42">42</abbr></abbrgrp> and this wide variation precludes the use of polyamine levels as a tumor marker as well as making detection of differences in polyamine concentrations in normal tissues of cancer patients and normal subjects difficult. The kinesis of polyamines may allow distant tissues and organs to influence polyamine levels of all cells in an organism.</p>
</sec>
</sec>
<sec><st><p>4. Polyamines and cancer spread</p></st>
<p>Patients with increased polyamine levels either in the blood or urine are reported to have more advanced disease and worse prognosis compared to those with low levels, regardless of the type of malignancy <abbrgrp><abbr bid="B4">4</abbr><abbr bid="B5">5</abbr><abbr bid="B6">6</abbr><abbr bid="B7">7</abbr><abbr bid="B8">8</abbr><abbr bid="B9">9</abbr></abbrgrp>. Because polyamines are essential for cell growth, the increased capability of polyamine synthesis could reflect enhanced tumor proliferation. Therefore, inhibition of polyamine synthesis and availability by cancer cells could retard cancer cell growth. The efficacy of polyamine depletion is prominent in animal experiments. Inhibition of polyamine synthesis by DL-&#945;-difluoromethylornithine (DFMO), an inhibitor of ODC that catalyzes the first rate-limiting step in polyamine biosynthesis, with or without methylglyoxal-bis-guanylhydrazone (MGBG), an inhibitor of S-Adenosylmethionine (SAM) that is required for polyamine synthesis, successfully suppressed tumor growth and prolonged survival of tumor-bearing animals <abbrgrp><abbr bid="B43">43</abbr><abbr bid="B44">44</abbr><abbr bid="B45">45</abbr><abbr bid="B46">46</abbr></abbrgrp>. Although the efficacy of polyamine restriction is not as apparent in humans as in animals <abbrgrp><abbr bid="B47">47</abbr><abbr bid="B48">48</abbr></abbrgrp>, inhibition of polyamine synthesis by DFMO successfully suppressed the progression of neoplastic disease <abbrgrp><abbr bid="B49">49</abbr><abbr bid="B50">50</abbr><abbr bid="B51">51</abbr><abbr bid="B52">52</abbr></abbrgrp>.</p>
<p>However, a major factor that directly influences the prognosis of patients with malignant disease is the capability of cancer cells to invade surrounding tissues and organs and evade immune cell defenses to metastasize to distant organs. In animal experiments, inhibition of polyamine synthesis by DFMO and/or MGBG not only reduced tumor growth but also decreased the amount of metastasis, resulting in prolonged survival of tumor bearing animals <abbrgrp><abbr bid="B43">43</abbr><abbr bid="B44">44</abbr><abbr bid="B46">46</abbr><abbr bid="B53">53</abbr><abbr bid="B54">54</abbr><abbr bid="B55">55</abbr></abbrgrp>. Therefore, the effect of polyamines on the metastatic potential of cancer cells, the host's anti-tumor immunity, and the corresponding mechanisms involved should be taken into consideration.</p>
</sec>
<sec><st><p>5. Mechanism of metastasis and involvement of polyamines (Figure <figr fid="F2">2</figr>)</p></st>
<p>There are several steps that occur during metastasis: separation of cancer cells from the tumor cluster (5-a); transmigration of cells from the original cluster to the circulation (5-b); and rooting and colonization in new organs and tissues (5-c) <abbrgrp><abbr bid="B56">56</abbr><abbr bid="B57">57</abbr></abbrgrp>. In addition, metastasis is completed only when cancer cells can successfully escape from the anti-tumor immune function of the host during this process (5-d). In this section, the mechanism of cancer metastasis and the involvement of polyamines are discussed.</p>
<sec><st><p>5-a. Separation of cancer cells from the tumor cluster, and the role of polyamines</p></st>
<p>Cancer metastasis begins when cancer cells separate from the tumor cluster. This separation is initiated by decreased cell adhesion, which is normally maintained by the presence of adhesion molecules involved in intercellular binding and binding between cells and the extracellular matrix. Hypoxia, a common condition in cancer tissues, exerts a strong pressure on cells to separate from the tumor cluster and migrate into circulation <abbrgrp><abbr bid="B58">58</abbr><abbr bid="B59">59</abbr></abbrgrp>. Despite their <it>de novo </it>angiogenesis, solid tumors have scattered regions where oxygen delivery is compromised due to diffusion limitations, structural abnormalities of tumor microvessels, and disturbed microcirculation <abbrgrp><abbr bid="B60">60</abbr></abbrgrp>. The cellular response to hypoxia involves the stabilization and resultant increase in levels of hypoxia inducible factor-1 (HIF-1), a transcription factor that enhances gene expression to promote angiogenesis, anaerobic metabolism, cell survival, and invasion <abbrgrp><abbr bid="B61">61</abbr></abbrgrp>. Among these, suppression of adhesion molecules induced by hypoxia-induced HIF-1 stabilization is a strong selective pressure that enhances outgrowth of cells with high-grade malignancy. CD44 and E-cadherin are adhesion molecules whose expression decreases in response to hypoxia <abbrgrp><abbr bid="B62">62</abbr><abbr bid="B63">63</abbr></abbrgrp>.</p>
<p>In cells exposed to chronic hypoxia, polyamine synthesis is decreased, while the ability to take up polyamines from the surroundings is increased <abbrgrp><abbr bid="B64">64</abbr><abbr bid="B65">65</abbr></abbrgrp>. Cells in a hypoxic environment have a resultant decrease in <it>de novo </it>polyamine synthesis and a concurrent increased capacity to take up polyamines from surrounding tissues, e.g. from cancer cells under normoxic conditions that are capable of producing abundant polyamines. We reported that cancer cells under hypoxia lose regulation of polyamine homeostasis and have increased polyamine uptake from surrounding tissues (Figure <figr fid="F2">2B, 1</figr>) <abbrgrp><abbr bid="B66">66</abbr></abbrgrp>. The expression of the adhesion molecule CD44 is suppressed in response to hypoxia. Reduced CD44 expression is reported to promote cancer metastasis and invasion, allowing detachment of cancer cells from the primary tumor cluster and seems to contribute to the increased migration capacity of hypoxic HT-29 cells <abbrgrp><abbr bid="B67">67</abbr><abbr bid="B68">68</abbr></abbrgrp>. In conjunction with hypoxia, increases in extracellular spermine specifically augmented hypoxia-induced decreases in CD44 expression, and these decreases correlated well with increased migration of cancer cells (HT-29) in a dose-dependent manner <abbrgrp><abbr bid="B66">66</abbr></abbrgrp>. In addition, several experiments indicated a possible role for polyamines in the invasive potential of cancer cells <abbrgrp><abbr bid="B53">53</abbr><abbr bid="B55">55</abbr><abbr bid="B69">69</abbr></abbrgrp>.</p>
<fig id="F2"><title><p>Figure 2</p></title><caption><p>Mechanism of cancer metastasis</p></caption><text>
   <p><b>Mechanism of cancer metastasis</b>. <b>A</b>. Cancer cells produce proteases to destroy the surrounding matrix, and produce proteins to create new vessels. In cancer tissues, there are areas where the oxygen supply is poor, which induces hypoxia. Hypoxic cancer cells lose their adhesion characteristics and have enhanced capacity for migration. <b>B</b>. (1) Polyamines synthesized by cancer cells are transferred to cancer cells under hypoxic conditions that have increased capacity for polyamine uptake and decreased intracellular polyamine synthesis. The increase in polyamine concentration due to increased polyamine uptake decreases adhesion of cancer cells by decreasing adhesion molecule expression. (2) Polyamines are transferred to the blood cells. Increased polyamine uptake by immune cells results in decreased production of tumoricidal cytokines and the amount of adhesion molecules, and these eventually attenuate the cytotoxic activities of immune cells.</p>
</text><graphic file="1756-9966-30-95-2" hint_layout="double"/></fig>
</sec>
<sec><st><p>5-b. Role of polyamines in cancer cell transmigration to the circulation</p></st>
<p>Cancer invasion is the process in which cancer cells migrate through surrounding tissues and enter into a blood vessel, which enables cancer cells to be transported throughout the body and establish secondary tumors. Blood vessel entry requires that cancer cells not only have increased motility but also secrete enzymes that degrade the surrounding cells' extracellular matrix (ECM), which is composed of the interstitial matrix and basement membrane, and provides structural support to cells. Cancer cells produce various proteinases, such as serine proteinase, matrix metalloproteinases (MMPs), cathepsins, and plasminogen activator that degrade the ECM <abbrgrp><abbr bid="B70">70</abbr><abbr bid="B71">71</abbr><abbr bid="B72">72</abbr></abbrgrp>. In addition, cancer cells have the ability to create new blood vessels in the tumor, i.e. angiogenesis, so that cancer cells can obtain supplies of blood and oxygen <abbrgrp><abbr bid="B73">73</abbr></abbrgrp>.</p>
<p>Increased polyamine synthesis appears to be accompanied by cancer invasiveness as ODC overexpression enhances the invasive characteristics of cancer cells <abbrgrp><abbr bid="B74">74</abbr></abbrgrp>. In contrast, inhibition of polyamine synthesis by the ODC inhibitor DFMO attenuates the invasive characteristics of cancer cells <abbrgrp><abbr bid="B53">53</abbr><abbr bid="B55">55</abbr><abbr bid="B75">75</abbr></abbrgrp>, and supplementation with polyamine reverses the DFMO-induced decrease in invasive qualities <abbrgrp><abbr bid="B75">75</abbr></abbrgrp>. The close correlation between increased polyamine synthesis and increased MMP synthesis has also been shown using DFMO, which caused decreases in cancer cell expression and concentrations of MMPs, such as matrilysin, meprin, and MMP-7 <abbrgrp><abbr bid="B76">76</abbr><abbr bid="B77">77</abbr></abbrgrp>.</p>
<p>As mentioned above, increased polyamine synthesis is also accompanied by angiogenesis that is stimulated by cellular production of several factors, including vascular endothelial growth factor, which allow tumor tissues to grow and survive by obtaining sufficient blood supplies <abbrgrp><abbr bid="B78">78</abbr></abbrgrp>. DFMO has been shown to exert its anti-tumor activity by inhibiting the proliferation of endothelial cells <abbrgrp><abbr bid="B79">79</abbr></abbrgrp>.</p>
</sec>
<sec><st><p>5-c. Possible role of polyamines on cell rooting and colonization at secondary tumor sites</p></st>
<p>Cancer cells that invade blood vessels and escape from immune system detection in circulation anchor to endothelial vasculature to establish new sites of growth. Upon vessel entry, cancer cells have access to abundant oxygen supplies that could enable cancer cells to restore their original activities such as increased gene expression that translates to enhanced enzymatic activities for polyamine synthesis, proteinase, and angiogenesis factors. Considering the results of our study, the expression of CD44 of normoxic cancer cells is higher than that of hypoxic cells <abbrgrp><abbr bid="B66">66</abbr></abbrgrp>, suggesting that the circulating cancer cells possibly recover their original adhesion characteristics. Once cancer cells anchor to the vessel wall of tissues and organs at secondary growth sites, they invade and rapidly grow because of their increased capacity to synthesize polyamines indispensable for cell growth and proteins that degrade the tissue matrix and create new vessels.</p>
</sec>
<sec><st><p>5-d. Polyamines help cancer cells escape immune system detection</p></st>
<p>Immune suppression, often observed in cancer patients, accelerates cancer spread. Various defects in cellular functions indicative of immune suppression have been reported, including attenuated adhesion properties of peripheral blood mononuclear cells (PBMCs) <abbrgrp><abbr bid="B80">80</abbr><abbr bid="B81">81</abbr><abbr bid="B82">82</abbr></abbrgrp>, impaired production of tumoricidal cytokines and chemokines <abbrgrp><abbr bid="B83">83</abbr><abbr bid="B84">84</abbr><abbr bid="B85">85</abbr></abbrgrp>, and decreased cytotoxic activity of killer cells, especially lymphokine activated killer (LAK) cells <abbrgrp><abbr bid="B86">86</abbr><abbr bid="B87">87</abbr><abbr bid="B88">88</abbr><abbr bid="B89">89</abbr></abbrgrp>. Several investigators have suggested that circulating factors that inhibit host immune activities are present in cancer patients <abbrgrp><abbr bid="B89">89</abbr><abbr bid="B90">90</abbr><abbr bid="B91">91</abbr></abbrgrp>. The suppression of immune function in cancer patients can be restored following tumor eradication, further suggesting the presence of increased immunosuppressive substance(s) in cancer patients <abbrgrp><abbr bid="B83">83</abbr><abbr bid="B84">84</abbr><abbr bid="B89">89</abbr><abbr bid="B91">91</abbr></abbrgrp>.</p>
<p>The increases in blood polyamine concentrations in cancer patients reflect increased polyamine concentrations in blood cells, mainly in red and white blood cells (Figure <figr fid="F2">2B, 2</figr>). The <it>in vitro </it>effects of polyamines on immune functions were first reported over 30 years ago <abbrgrp><abbr bid="B92">92</abbr></abbrgrp>. However, later analysis revealed that the reported immunosuppressive effects are induced not by the direct effect of polyamines but by substances produced by the interaction between polyamines and serum amine oxidase, present exclusively in ruminants, making these results difficult to extend to humans, which lack this enzyme. Nonetheless, animal experiments have shown that polyamine deprivation prevents the development of tumor-induced immunosuppression <abbrgrp><abbr bid="B93">93</abbr></abbrgrp>.</p>
<p>The adhesion characteristics of immune cells are important for eliciting anti-tumor cytotoxic activity, because adhesion is crucial for immune cell recognition of tumor cells <abbrgrp><abbr bid="B94">94</abbr></abbrgrp>. Due to decreased adhesion, immune cells fail to recognize cancer cells or exert tumoricidal activities. Such decreases in immune cell adhesion are observed not only in cancer patients but also in patients having non-cancerous lesions <abbrgrp><abbr bid="B82">82</abbr></abbrgrp>. These findings suggest the possibility that common factor(s), not specifically produced in cancer patients, can induce immunosuppressive conditions. Polyamines are one such factor, because blood polyamine levels, namely levels in blood cells including immune cells, are often increased in patients with various diseases <abbrgrp><abbr bid="B36">36</abbr><abbr bid="B95">95</abbr><abbr bid="B96">96</abbr><abbr bid="B97">97</abbr></abbrgrp>.</p>
<p>Immune cells also take up polyamines form their surroundings <abbrgrp><abbr bid="B98">98</abbr><abbr bid="B99">99</abbr></abbrgrp>, and the increase in blood polyamine concentrations often observed in cancer patients as well as in patients with other diseases reflects the increased polyamine levels in leukocytes <abbrgrp><abbr bid="B36">36</abbr><abbr bid="B100">100</abbr></abbrgrp>. We have shown that increased concentrations of spermine or spermidine in cultured human PBMCs suppress adhesion without sacrificing cell viability and activity.</p>
<p>The time- and dose-dependent decrease in adhesion produced by polyamines was accompanied by decreases in the expression of lymphocyte function-associated antigen-1 (LFA-1), which consists of an integrin alpha L (CD11a) and beta 2 (CD18) chain <abbrgrp><abbr bid="B41">41</abbr></abbrgrp>. Polyamines in particular decrease the number of cells expressing bright CD11a. Such suppression was exclusively observed for LFA-1 with most other adhesion molecules tested unaffected by polyamines. The suppression of LFA-1 expression by polyamines was further confirmed in human healthy volunteers with polyamines suppressing LFA-1 expression on PBMCs, regardless of the volunteer's age <abbrgrp><abbr bid="B41">41</abbr></abbrgrp>. In addition to LFA-1 suppression by polyamines, the number of CD56 bright cells was decreased by polyamines <it>in vitro</it>, although the effect was not confirmed <it>in vivo</it>. LFA-1 and CD56 contribute to the induction of tumoricidal cell activities, especially lymphokine activated killer (LAK) activity <abbrgrp><abbr bid="B101">101</abbr><abbr bid="B102">102</abbr></abbrgrp>. LAK cells, which have tumoricidal activities against established (existing) tumors, are induced by co-culture with IL-2 <abbrgrp><abbr bid="B103">103</abbr><abbr bid="B104">104</abbr></abbrgrp>. In animal experiments, polyamine deprivation reversed the tumor inoculation-induced suppression of IL-2 production without decreasing the number of T lymphocytes <abbrgrp><abbr bid="B93">93</abbr></abbrgrp>. In addition, polyamines (spermine and spermidine) inhibit the production of tumoricidal cytokines, such as tumor necrosis factor (TNF), and chemokines <it>in vitro</it>, while they do not inhibit production of transforming growth factor beta, which has immunosuppressive properties <abbrgrp><abbr bid="B105">105</abbr><abbr bid="B106">106</abbr><abbr bid="B107">107</abbr></abbrgrp>. Conversely, in animal experiments, polyamine deprivation has been shown to enhance chemokine production, reverse tumor inoculation-induced inhibition of killer cell activity, and prevent tumor-induced immune suppression <abbrgrp><abbr bid="B108">108</abbr><abbr bid="B109">109</abbr></abbrgrp>.</p>
<p>TNF is able to induce apoptotic cell death and to attack and destroy cancer cells <abbrgrp><abbr bid="B110">110</abbr></abbrgrp>, while LFA-1 and CD56, especially bright CD11a and bright CD56 cells, are required for the induction of LAK cell cytotoxic activity <abbrgrp><abbr bid="B111">111</abbr><abbr bid="B112">112</abbr></abbrgrp>. Polyamines suppress LAK cytotoxicity without decreasing cell viability and activity <it>in vitro</it>, and the changes in blood spermine levels are negatively associated with changes in LAK cytotoxicity in cancer patients <abbrgrp><abbr bid="B42">42</abbr></abbrgrp>.</p>
</sec>
</sec>
<sec><st><p>6. Sources of polyamines other than cancer cells</p></st>
<p>Food is an important source of polyamines. Polyamines in the intestinal lumen are absorbed quickly and distributed to all organs and tissues <abbrgrp><abbr bid="B29">29</abbr><abbr bid="B39">39</abbr><abbr bid="B40">40</abbr></abbrgrp>. Moreover, continuous intake of polyamine-rich food gradually increases blood polyamine levels <abbrgrp><abbr bid="B30">30</abbr><abbr bid="B31">31</abbr></abbrgrp>. Therefore, the restricted intake of food polyamine and inhibition of polyamine synthesis by microbiota in the intestine with or without inhibitor-induced inhibition of polyamine synthesis is reported to have favorable effects on cancer therapy <abbrgrp><abbr bid="B33">33</abbr><abbr bid="B113">113</abbr><abbr bid="B114">114</abbr><abbr bid="B115">115</abbr></abbrgrp>.</p>
<p>Trauma, such as surgery, is itself considered to increase the risk of cancer spread through various mechanisms <abbrgrp><abbr bid="B116">116</abbr><abbr bid="B117">117</abbr><abbr bid="B118">118</abbr></abbrgrp>. Blood concentration and urinary excretion of polyamines are known to increase after surgery, although the origin of this increase is not well established <abbrgrp><abbr bid="B97">97</abbr><abbr bid="B119">119</abbr></abbrgrp>. Our previous study showed that increases in blood polyamine levels are inversely associated with anti-tumor LAK cytotoxicities in patients who have undergone surgery <abbrgrp><abbr bid="B42">42</abbr></abbrgrp>. In addition to mechanisms previously postulated for post-traumatic cancer spread, post-operative increases in polyamines may be another factor that accelerates tumor growth.</p>
</sec>
<sec><st><p>Conclusion</p></st>
<p>As polyamines are essential for cell growth, one of the mechanisms by which polyamines accelerate tumor growth is through the increased availability of this indispensable growth factor. In addition, polyamines seem to accelerate tumor invasion and metastasis not only by suppressing immune system activity against established (already existing) tumors but also by enhancing the ability of invasive and metastatic capability of cancer cells. When considering the mechanism by which polyamines elicit their biological activities on immune and cancer cell functions, inhibition of polyamine uptake by cells seems to be an important target for polyamine-based cancer therapy particularly because inhibition of polyamine synthesis alone failed to produce a favorable effect on cancer treatments in several clinical trials. In addition to inhibiting polyamine synthesis and supply, inhibition of polyamine uptake via the polyamine transporter may have beneficial effects <abbrgrp><abbr bid="B120">120</abbr><abbr bid="B121">121</abbr></abbrgrp>.</p>
</sec>
<sec><st><p>List of abbreviations</p></st>
<p>APAO: N<sup>1</sup>-acetylpolyamine oxidase; DFMO: D, L-&#945;-difluoromethylornithine; ECM: extracellular matrix; HIF-1: hypoxia inducible factor-1; LAK: lymphokine activated killer; LFA-1: lymphocyte function-associated antigen-1; MGBG: methylglyoxal bis-(guanylhydrazone); MMPs: matrix metalloproteinases; ODC: ornithine decarboxylase; PBMCs: peripheral blood mononuclear cells; SAM: S-Adenosylmethionine; SSAT: spermidine/spermine N1-acetyltransferase; TNF: tumor necrosis factor.</p>
</sec>
<sec><st><p>Competing interests</p></st>
<p>The authors declare that they have no competing interests.</p>
</sec>
<sec><st><p>Authors' contributions</p></st>
<p>KS contributed solely to the writing and submission of this work.</p>
</sec>
</bdy>
<bm>
<refgrp><bibl id="B1"><title><p>Polyamines as markers of response and disease activity in cancer chemotherapy</p></title><aug><au><snm>Durie</snm><fnm>BG</fnm></au><au><snm>Salmon</snm><fnm>SE</fnm></au><au><snm>Russell</snm><fnm>DH</fnm></au></aug><source>Cancer Res</source><pubdate>1977</pubdate><volume>37</volume><fpage>214</fpage><lpage>221</lpage><xrefbib><pubid idtype="pmpid" link="fulltext">830407</pubid></xrefbib></bibl><bibl id="B2"><title><p>Polyamines in colorectal cancer. Evaluation of polyamine concentrations in the colon tissue, serum, and urine of 50 patients with colorectal cancer</p></title><aug><au><snm>Loser</snm><fnm>C</fnm></au><au><snm>Folsch</snm><fnm>UR</fnm></au><au><snm>Paprotny</snm><fnm>C</fnm></au><au><snm>Creutzfeldt</snm><fnm>W</fnm></au></aug><source>Cancer</source><pubdate>1990</pubdate><volume>65</volume><fpage>958</fpage><lpage>966</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1002/1097-0142(19900215)65:4&lt;958::AID-CNCR2820650423&gt;3.0.CO;2-Z</pubid><pubid idtype="pmpid">2297664</pubid></pubidlist></xrefbib></bibl><bibl id="B3"><title><p>Red blood cell polyamines as biochemical markers of supratentorial malignant gliomas</p></title><aug><au><snm>Chatel</snm><fnm>M</fnm></au><au><snm>Darcel</snm><fnm>F</fnm></au><au><snm>Quemener</snm><fnm>V</fnm></au><au><snm>Hercouet</snm><fnm>H</fnm></au><au><snm>Moulinoux</snm><fnm>JP</fnm></au></aug><source>Anticancer Res</source><pubdate>1987</pubdate><volume>7</volume><fpage>33</fpage><lpage>38</lpage><xrefbib><pubid idtype="pmpid">3566181</pubid></xrefbib></bibl><bibl id="B4"><title><p>Urinary polyamines as a tumor marker</p></title><aug><au><snm>Kubota</snm><fnm>S</fnm></au><au><snm>Okada</snm><fnm>M</fnm></au><au><snm>Yoshimoto</snm><fnm>M</fnm></au><au><snm>Murata</snm><fnm>N</fnm></au><au><snm>Yamasaki</snm><fnm>Z</fnm></au><au><snm>Wada</snm><fnm>T</fnm></au><au><snm>Imahori</snm><fnm>K</fnm></au><au><snm>Ohsawa</snm><fnm>N</fnm></au><au><snm>Takaku</snm><fnm>F</fnm></au></aug><source>Cancer Detect Prev</source><pubdate>1985</pubdate><volume>8</volume><fpage>189</fpage><lpage>192</lpage><xrefbib><pubid idtype="pmpid">4064039</pubid></xrefbib></bibl><bibl id="B5"><title><p>Elevated contents of spermidine and spermine in the erythrocytes of cancer patients</p></title><aug><au><snm>Uehara</snm><fnm>N</fnm></au><au><snm>Shirakawa</snm><fnm>S</fnm></au><au><snm>Uchino</snm><fnm>H</fnm></au><au><snm>Saeki</snm><fnm>Y</fnm></au></aug><source>Cancer</source><pubdate>1980</pubdate><volume>45</volume><fpage>108</fpage><lpage>111</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1002/1097-0142(19800101)45:1&lt;108::AID-CNCR2820450120&gt;3.0.CO;2-W</pubid><pubid idtype="pmpid">7350997</pubid></pubidlist></xrefbib></bibl><bibl id="B6"><title><p>Erythrocyte polyamines and prognosis in stage D2 prostatic carcinoma patients</p></title><aug><au><snm>Cipolla</snm><fnm>B</fnm></au><au><snm>Guille</snm><fnm>F</fnm></au><au><snm>Moulinoux</snm><fnm>JP</fnm></au><au><snm>Bansard</snm><fnm>JY</fnm></au><au><snm>Roth</snm><fnm>S</fnm></au><au><snm>Staerman</snm><fnm>F</fnm></au><au><snm>Corbel</snm><fnm>L</fnm></au><au><snm>Quemener</snm><fnm>V</fnm></au><au><snm>Lobel</snm><fnm>B</fnm></au></aug><source>J Urol</source><pubdate>1994</pubdate><volume>151</volume><fpage>629</fpage><lpage>633</lpage><xrefbib><pubid idtype="pmpid">7508520</pubid></xrefbib></bibl><bibl id="B7"><title><p>Polyamine levels of human colorectal adenocarcinomas are correlated with tumor stage and grade</p></title><aug><au><snm>Weiss</snm><fnm>TS</fnm></au><au><snm>Bernhardt</snm><fnm>G</fnm></au><au><snm>Buschauer</snm><fnm>A</fnm></au><au><snm>Thasler</snm><fnm>WE</fnm></au><au><snm>Dolgner</snm><fnm>D</fnm></au><au><snm>Zirngibl</snm><fnm>H</fnm></au><au><snm>Jauch</snm><fnm>KW</fnm></au></aug><source>Int J Colorectal Dis</source><pubdate>2002</pubdate><volume>17</volume><fpage>381</fpage><lpage>387</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1007/s00384-002-0394-7</pubid><pubid idtype="pmpid" link="fulltext">12355213</pubid></pubidlist></xrefbib></bibl><bibl id="B8"><title><p>Prognostic value of tissue polyamine levels in human colorectal carcinoma</p></title><aug><au><snm>Linsalata</snm><fnm>M</fnm></au><au><snm>Caruso</snm><fnm>MG</fnm></au><au><snm>Leo</snm><fnm>S</fnm></au><au><snm>Guerra</snm><fnm>V</fnm></au><au><snm>D&apos;Attoma</snm><fnm>B</fnm></au><au><snm>Di Leo</snm><fnm>A</fnm></au></aug><source>Anticancer Res</source><pubdate>2002</pubdate><volume>22</volume><fpage>2465</fpage><lpage>2469</lpage><xrefbib><pubid idtype="pmpid">12174945</pubid></xrefbib></bibl><bibl id="B9"><title><p>Erythrocyte spermine levels: a prognostic parameter in childhood common acute lymphoblastic leukemia</p></title><aug><au><snm>Bergeron</snm><fnm>C</fnm></au><au><snm>Bansard</snm><fnm>JY</fnm></au><au><snm>Le Moine</snm><fnm>P</fnm></au><au><snm>Bouet</snm><fnm>F</fnm></au><au><snm>Goasguen</snm><fnm>JE</fnm></au><au><snm>Moulinoux</snm><fnm>JP</fnm></au><au><snm>Le Gall</snm><fnm>E</fnm></au><au><snm>Catros-Quemener</snm><fnm>V</fnm></au></aug><source>Leukemia</source><pubdate>1997</pubdate><volume>11</volume><fpage>31</fpage><lpage>36</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1038/sj.leu.2400531</pubid><pubid idtype="pmpid">9001415</pubid></pubidlist></xrefbib></bibl><bibl id="B10"><title><p>Clinical relevance of polyamines</p></title><aug><au><snm>Russell</snm><fnm>DH</fnm></au></aug><source>Crit Rev Clin Lab Sci</source><pubdate>1983</pubdate><volume>18</volume><fpage>261</fpage><lpage>311</lpage><xrefbib><pubid idtype="pmpid">6339165</pubid></xrefbib></bibl><bibl id="B11"><title><p>Polyamines and protein kinase II. Effect of polyamines on cyclic AMP--dependent protein kinase from rat liver</p></title><aug><au><snm>Hochman</snm><fnm>J</fnm></au><au><snm>Katz</snm><fnm>A</fnm></au><au><snm>Bachrach</snm><fnm>U</fnm></au></aug><source>Life Sci</source><pubdate>1978</pubdate><volume>22</volume><fpage>1481</fpage><lpage>1484</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1016/0024-3205(78)90002-4</pubid><pubid idtype="pmpid">209271</pubid></pubidlist></xrefbib></bibl><bibl id="B12"><title><p>Activation of the proto-oncogene c-myc and c-fos by c-ras: involvement of polyamines</p></title><aug><au><snm>Tabib</snm><fnm>A</fnm></au><au><snm>Bachrach</snm><fnm>U</fnm></au></aug><source>Biochem Biophys Res Commun</source><pubdate>1994</pubdate><volume>202</volume><fpage>720</fpage><lpage>727</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1006/bbrc.1994.1990</pubid><pubid idtype="pmpid" link="fulltext">8048943</pubid></pubidlist></xrefbib></bibl><bibl id="B13"><title><p>Polyamines alter sequence-specific DNA-protein interactions</p></title><aug><au><snm>Panagiotidis</snm><fnm>CA</fnm></au><au><snm>Artandi</snm><fnm>S</fnm></au><au><snm>Calame</snm><fnm>K</fnm></au><au><snm>Silverstein</snm><fnm>SJ</fnm></au></aug><source>Nucleic Acids Res</source><pubdate>1995</pubdate><volume>23</volume><fpage>1800</fpage><lpage>1809</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1093/nar/23.10.1800</pubid><pubid idtype="pmcid">306939</pubid><pubid idtype="pmpid" link="fulltext">7784186</pubid></pubidlist></xrefbib></bibl><bibl id="B14"><title><p>Polyamine-dependent gene expression</p></title><aug><au><snm>Childs</snm><fnm>AC</fnm></au><au><snm>Mehta</snm><fnm>DJ</fnm></au><au><snm>Gerner</snm><fnm>EW</fnm></au></aug><source>Cell Mol Life Sci</source><pubdate>2003</pubdate><volume>60</volume><fpage>1394</fpage><lpage>1406</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1007/s00018-003-2332-4</pubid><pubid idtype="pmpid" link="fulltext">12943227</pubid></pubidlist></xrefbib></bibl><bibl id="B15"><title><p>Polyamine oxidase, properties and functions</p></title><aug><au><snm>Seiler</snm><fnm>N</fnm></au></aug><source>Prog Brain Res</source><pubdate>1995</pubdate><volume>106</volume><fpage>333</fpage><lpage>344</lpage><xrefbib><pubid idtype="pmpid">8584670</pubid></xrefbib></bibl><bibl id="B16"><title><p>Polyamine catabolism and disease</p></title><aug><au><snm>Casero</snm><fnm>RA</fnm></au><au><snm>Pegg</snm><fnm>AE</fnm></au></aug><source>Biochem J</source><pubdate>2009</pubdate><volume>421</volume><fpage>323</fpage><lpage>338</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1042/BJ20090598</pubid><pubid idtype="pmcid">2756025</pubid><pubid idtype="pmpid" link="fulltext">19589128</pubid></pubidlist></xrefbib></bibl><bibl id="B17"><title><p>Mammalian polyamine metabolism and function</p></title><aug><au><snm>Pegg</snm><fnm>AE</fnm></au></aug><source>IUBMB Life</source><pubdate>2009</pubdate><volume>61</volume><fpage>880</fpage><lpage>894</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1002/iub.230</pubid><pubid idtype="pmcid">2753421</pubid><pubid idtype="pmpid" link="fulltext">19603518</pubid></pubidlist></xrefbib></bibl><bibl id="B18"><title><p>Polyamines and cancer: old molecules, new understanding</p></title><aug><au><snm>Gerner</snm><fnm>EW</fnm></au><au><snm>Meyskens</snm><fnm>FL</fnm><suf>Jr</suf></au></aug><source>Nat Rev Cancer</source><pubdate>2004</pubdate><volume>4</volume><fpage>781</fpage><lpage>792</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1038/nrc1454</pubid><pubid idtype="pmpid" link="fulltext">15510159</pubid></pubidlist></xrefbib></bibl><bibl id="B19"><title><p>APC-dependent changes in expression of genes influencing polyamine metabolism, and consequences for gastrointestinal carcinogenesis, in the Min mouse</p></title><aug><au><snm>Erdman</snm><fnm>SH</fnm></au><au><snm>Ignatenko</snm><fnm>NA</fnm></au><au><snm>Powell</snm><fnm>MB</fnm></au><au><snm>Blohm-Mangone</snm><fnm>KA</fnm></au><au><snm>Holubec</snm><fnm>H</fnm></au><au><snm>Guillen-Rodriguez</snm><fnm>JM</fnm></au><au><snm>Gerner</snm><fnm>EW</fnm></au></aug><source>Carcinogenesis</source><pubdate>1999</pubdate><volume>20</volume><fpage>1709</fpage><lpage>1713</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1093/carcin/20.9.1709</pubid><pubid idtype="pmpid" link="fulltext">10469614</pubid></pubidlist></xrefbib></bibl><bibl id="B20"><title><p>Polyamine levels in healthy and tumor tissues of patients with colon adenocarcinoma</p></title><aug><au><snm>Becciolini</snm><fnm>A</fnm></au><au><snm>Porciani</snm><fnm>S</fnm></au><au><snm>Lanini</snm><fnm>A</fnm></au><au><snm>Balzi</snm><fnm>M</fnm></au><au><snm>Cionini</snm><fnm>L</fnm></au><au><snm>Bandettini</snm><fnm>L</fnm></au></aug><source>Dis Colon Rectum</source><pubdate>1991</pubdate><volume>34</volume><fpage>167</fpage><lpage>173</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1007/BF02049993</pubid><pubid idtype="pmpid">1993414</pubid></pubidlist></xrefbib></bibl><bibl id="B21"><title><p>Prognostic value of ornithine decarboxylase and polyamines in human breast cancer: correlation with clinicopathologic parameters</p></title><aug><au><snm>Canizares</snm><fnm>F</fnm></au><au><snm>Salinas</snm><fnm>J</fnm></au><au><snm>de las Heras</snm><fnm>M</fnm></au><au><snm>Diaz</snm><fnm>J</fnm></au><au><snm>Tovar</snm><fnm>I</fnm></au><au><snm>Martinez</snm><fnm>P</fnm></au><au><snm>Penafiel</snm><fnm>R</fnm></au></aug><source>Clin Cancer Res</source><pubdate>1999</pubdate><volume>5</volume><fpage>2035</fpage><lpage>2041</lpage><xrefbib><pubid idtype="pmpid" link="fulltext">10473083</pubid></xrefbib></bibl><bibl id="B22"><title><p>Two chromosomal locations for human ornithine decarboxylase gene sequences and elevated expression in colorectal neoplasia</p></title><aug><au><snm>Radford</snm><fnm>DM</fnm></au><au><snm>Nakai</snm><fnm>H</fnm></au><au><snm>Eddy</snm><fnm>RL</fnm></au><au><snm>Haley</snm><fnm>LL</fnm></au><au><snm>Byers</snm><fnm>MG</fnm></au><au><snm>Henry</snm><fnm>WM</fnm></au><au><snm>Lawrence</snm><fnm>DD</fnm></au><au><snm>Porter</snm><fnm>CW</fnm></au><au><snm>Shows</snm><fnm>TB</fnm></au></aug><source>Cancer Res</source><pubdate>1990</pubdate><volume>50</volume><fpage>6146</fpage><lpage>6153</lpage><xrefbib><pubid idtype="pmpid" link="fulltext">1976038</pubid></xrefbib></bibl><bibl id="B23"><title><p>Polyamines in colorectal cancer</p></title><aug><au><snm>Kingsnorth</snm><fnm>AN</fnm></au><au><snm>Lumsden</snm><fnm>AB</fnm></au><au><snm>Wallace</snm><fnm>HM</fnm></au></aug><source>Br J Surg</source><pubdate>1984</pubdate><volume>71</volume><fpage>791</fpage><lpage>794</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1002/bjs.1800711019</pubid><pubid idtype="pmpid">6487981</pubid></pubidlist></xrefbib></bibl><bibl id="B24"><title><p>High ornithine decarboxylase activity and polyamine levels in human colorectal neoplasia</p></title><aug><au><snm>LaMuraglia</snm><fnm>GM</fnm></au><au><snm>Lacaine</snm><fnm>F</fnm></au><au><snm>Malt</snm><fnm>RA</fnm></au></aug><source>Ann Surg</source><pubdate>1986</pubdate><volume>204</volume><fpage>89</fpage><lpage>93</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1097/00000658-198607000-00013</pubid><pubid idtype="pmcid">1251228</pubid><pubid idtype="pmpid">3729588</pubid></pubidlist></xrefbib></bibl><bibl id="B25"><title><p>Selective elevation of the N1-acetylspermidine level in human colorectal adenocarcinomas</p></title><aug><au><snm>Takenoshita</snm><fnm>S</fnm></au><au><snm>Matsuzaki</snm><fnm>S</fnm></au><au><snm>Nakano</snm><fnm>G</fnm></au><au><snm>Kimura</snm><fnm>H</fnm></au><au><snm>Hoshi</snm><fnm>H</fnm></au><au><snm>Shoda</snm><fnm>H</fnm></au><au><snm>Nakamura</snm><fnm>T</fnm></au></aug><source>Cancer Res</source><pubdate>1984</pubdate><volume>44</volume><fpage>845</fpage><lpage>847</lpage><xrefbib><pubid idtype="pmpid" link="fulltext">6692383</pubid></xrefbib></bibl><bibl id="B26"><title><p>Spermidine uptake by erythrocytes from normal and Lewis lung carcinoma (3LL) grafted mice: I. In vitro study</p></title><aug><au><snm>Moulinoux</snm><fnm>JP</fnm></au><au><snm>Quemener</snm><fnm>V</fnm></au><au><snm>Khan</snm><fnm>NA</fnm></au><au><snm>Delcros</snm><fnm>JG</fnm></au><au><snm>Havouis</snm><fnm>R</fnm></au></aug><source>Anticancer Res</source><pubdate>1989</pubdate><volume>9</volume><fpage>1057</fpage><lpage>1062</lpage><xrefbib><pubid idtype="pmpid">2817786</pubid></xrefbib></bibl><bibl id="B27"><title><p>Rapid absorption of luminal polyamines in a rat small intestine ex vivo model</p></title><aug><au><snm>Uda</snm><fnm>K</fnm></au><au><snm>Tsujikawa</snm><fnm>T</fnm></au><au><snm>Fujiyama</snm><fnm>Y</fnm></au><au><snm>Bamba</snm><fnm>T</fnm></au></aug><source>J Gastroenterol Hepatol</source><pubdate>2003</pubdate><volume>18</volume><fpage>554</fpage><lpage>559</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1046/j.1440-1746.2003.03020.x</pubid><pubid idtype="pmpid" link="fulltext">12702048</pubid></pubidlist></xrefbib></bibl><bibl id="B28"><title><p>Luminal and basolateral polyamine uptake by rat small intestine stimulated to grow by Phaseolus vulgaris lectin phytohaemagglutinin in vivo</p></title><aug><au><snm>Bardocz</snm><fnm>S</fnm></au><au><snm>Brown</snm><fnm>DS</fnm></au><au><snm>Grant</snm><fnm>G</fnm></au><au><snm>Pusztai</snm><fnm>A</fnm></au></aug><source>Biochim Biophys Acta</source><pubdate>1990</pubdate><volume>1034</volume><fpage>46</fpage><lpage>52</lpage><xrefbib><pubid idtype="pmpid" link="fulltext">2109637</pubid></xrefbib></bibl><bibl id="B29"><title><p>Polyamines in food--implications for growth and health</p></title><aug><au><snm>Bardocz</snm><fnm>S</fnm></au><au><snm>Grant</snm><fnm>G</fnm></au><au><snm>Brown</snm><fnm>DS</fnm></au><au><snm>Ralph</snm><fnm>A</fnm></au><au><snm>Pusztai</snm><fnm>A</fnm></au></aug><source>J Nutr Biochem</source><pubdate>1993</pubdate><volume>4</volume><fpage>66</fpage><lpage>71</lpage><xrefbib><pubid idtype="doi">10.1016/0955-2863(93)90001-D</pubid></xrefbib></bibl><bibl id="B30"><title><p>Long-term oral polyamine intake increases blood polyamine concentrations</p></title><aug><au><snm>Soda</snm><fnm>K</fnm></au><au><snm>Kano</snm><fnm>Y</fnm></au><au><snm>Sakuragi</snm><fnm>M</fnm></au><au><snm>Takao</snm><fnm>K</fnm></au><au><snm>Lefor</snm><fnm>A</fnm></au><au><snm>Konishi</snm><fnm>F</fnm></au></aug><source>J Nutr Sci Vitaminol (Tokyo)</source><pubdate>2009</pubdate><volume>55</volume><fpage>361</fpage><lpage>366</lpage><xrefbib><pubid idtype="doi">10.3177/jnsv.55.361</pubid></xrefbib></bibl><bibl id="B31"><title><p>Polyamine-rich food decreases age-associated pathology and mortality in aged mice</p></title><aug><au><snm>Soda</snm><fnm>K</fnm></au><au><snm>Dobashi</snm><fnm>Y</fnm></au><au><snm>Kano</snm><fnm>Y</fnm></au><au><snm>Tsujinaka</snm><fnm>S</fnm></au><au><snm>Konishi</snm><fnm>F</fnm></au></aug><source>Exp Gerontol</source><pubdate>2009</pubdate><volume>44</volume><fpage>727</fpage><lpage>732</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1016/j.exger.2009.08.013</pubid><pubid idtype="pmpid" link="fulltext">19735716</pubid></pubidlist></xrefbib></bibl><bibl id="B32"><title><p>Effects of dietary polyamines and clofibrate on metabolism of polyamines in the rat</p></title><aug><au><snm>Brodal</snm><fnm>BP</fnm></au><au><snm>Eliassen</snm><fnm>KA</fnm></au><au><snm>Ronning</snm><fnm>H</fnm></au><au><snm>Osmundsen</snm><fnm>H</fnm></au></aug><source>J Nutr Biochem</source><pubdate>1999</pubdate><volume>10</volume><fpage>700</fpage><lpage>708</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1016/S0955-2863(99)00058-3</pubid><pubid idtype="pmpid" link="fulltext">15539269</pubid></pubidlist></xrefbib></bibl><bibl id="B33"><title><p>The gastrointestinal tract as polyamine source for tumor growth</p></title><aug><au><snm>Sarhan</snm><fnm>S</fnm></au><au><snm>Knodgen</snm><fnm>B</fnm></au><au><snm>Seiler</snm><fnm>N</fnm></au></aug><source>Anticancer Res</source><pubdate>1989</pubdate><volume>9</volume><fpage>215</fpage><lpage>223</lpage><xrefbib><pubid idtype="pmpid">2495754</pubid></xrefbib></bibl><bibl id="B34"><title><p>Polyamine uptake by human colon carcinoma cell line CaCo-2</p></title><aug><au><snm>D&apos;Agostino</snm><fnm>L</fnm></au><au><snm>Pignata</snm><fnm>S</fnm></au><au><snm>Daniele</snm><fnm>B</fnm></au><au><snm>D&apos;Adamo</snm><fnm>G</fnm></au><au><snm>Ferraro</snm><fnm>C</fnm></au><au><snm>Silvestro</snm><fnm>G</fnm></au><au><snm>Tagliaferri</snm><fnm>P</fnm></au><au><snm>Contegiacomo</snm><fnm>A</fnm></au><au><snm>Gentile</snm><fnm>R</fnm></au><au><snm>Tritto</snm><fnm>G</fnm></au><etal/></aug><source>Digestion</source><pubdate>1990</pubdate><volume>46</volume><issue>Suppl 2</issue><fpage>352</fpage><lpage>359</lpage><xrefbib><pubid idtype="pmpid">2262067</pubid></xrefbib></bibl><bibl id="B35"><title><p>Polyamine uptake by bovine adrenocortical cells</p></title><aug><au><snm>Feige</snm><fnm>JJ</fnm></au><au><snm>Chambaz</snm><fnm>EM</fnm></au></aug><source>Biochim Biophys Acta</source><pubdate>1985</pubdate><volume>846</volume><fpage>93</fpage><lpage>100</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1016/0167-4889(85)90114-4</pubid><pubid idtype="pmpid" link="fulltext">2990582</pubid></pubidlist></xrefbib></bibl><bibl id="B36"><title><p>Polyamine compartmentalization in various human disease states</p></title><aug><au><snm>Cooper</snm><fnm>KD</fnm></au><au><snm>Shukla</snm><fnm>JB</fnm></au><au><snm>Rennert</snm><fnm>OM</fnm></au></aug><source>Clin Chim Acta</source><pubdate>1978</pubdate><volume>82</volume><fpage>1</fpage><lpage>7</lpage><xrefbib><pubid idtype="pmpid">618672</pubid></xrefbib></bibl><bibl id="B37"><title><p>Polyamine levels and gastrin receptors in colon cancers</p></title><aug><au><snm>Upp</snm><fnm>JR</fnm><suf>Jr</suf></au><au><snm>Saydjari</snm><fnm>R</fnm></au><au><snm>Townsend</snm><fnm>CM</fnm><suf>Jr</suf></au><au><snm>Singh</snm><fnm>P</fnm></au><au><snm>Barranco</snm><fnm>SC</fnm></au><au><snm>Thompson</snm><fnm>JC</fnm></au></aug><source>Ann Surg</source><pubdate>1988</pubdate><volume>207</volume><fpage>662</fpage><lpage>669</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1097/00000658-198806000-00004</pubid><pubid idtype="pmcid">1493553</pubid><pubid idtype="pmpid">3389934</pubid></pubidlist></xrefbib></bibl><bibl id="B38"><title><p>Ornithine decarboxylase and polyamines in colorectal neoplasia and mucosa</p></title><aug><au><snm>Hixson</snm><fnm>LJ</fnm></au><au><snm>Garewal</snm><fnm>HS</fnm></au><au><snm>McGee</snm><fnm>DL</fnm></au><au><snm>Sloan</snm><fnm>D</fnm></au><au><snm>Fennerty</snm><fnm>MB</fnm></au><au><snm>Sampliner</snm><fnm>RE</fnm></au><au><snm>Gerner</snm><fnm>EW</fnm></au></aug><source>Cancer Epidemiol Biomarkers Prev</source><pubdate>1993</pubdate><volume>2</volume><fpage>369</fpage><lpage>374</lpage><xrefbib><pubid idtype="pmpid" link="fulltext">8348060</pubid></xrefbib></bibl><bibl id="B39"><title><p>Gastrointestinal luminal polyamines: cellular accumulation and enterohepatic circulation</p></title><aug><au><snm>Osborne</snm><fnm>DL</fnm></au><au><snm>Seidel</snm><fnm>ER</fnm></au></aug><source>Am J Physiol</source><pubdate>1990</pubdate><volume>258</volume><fpage>G576</fpage><lpage>584</lpage><xrefbib><pubid idtype="pmpid" link="fulltext">2333971</pubid></xrefbib></bibl><bibl id="B40"><title><p>Fate of orally administered 15N-labeled polyamines in rats bearing solid tumors</p></title><aug><au><snm>Kobayashi</snm><fnm>M</fnm></au><au><snm>Xu</snm><fnm>YJ</fnm></au><au><snm>Samejima</snm><fnm>K</fnm></au><au><snm>Goda</snm><fnm>H</fnm></au><au><snm>Niitsu</snm><fnm>M</fnm></au><au><snm>Takahashi</snm><fnm>M</fnm></au><au><snm>Hashimoto</snm><fnm>Y</fnm></au></aug><source>Biol Pharm Bull</source><pubdate>2003</pubdate><volume>26</volume><fpage>285</fpage><lpage>288</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1248/bpb.26.285</pubid><pubid idtype="pmpid" link="fulltext">12612433</pubid></pubidlist></xrefbib></bibl><bibl id="B41"><title><p>Spermine, a natural polyamine, suppresses LFA-1 expression on human lymphocyte</p></title><aug><au><snm>Soda</snm><fnm>K</fnm></au><au><snm>Kano</snm><fnm>Y</fnm></au><au><snm>Nakamura</snm><fnm>T</fnm></au><au><snm>Kasono</snm><fnm>K</fnm></au><au><snm>Kawakami</snm><fnm>M</fnm></au><au><snm>Konishi</snm><fnm>F</fnm></au></aug><source>J Immunol</source><pubdate>2005</pubdate><volume>175</volume><fpage>237</fpage><lpage>245</lpage><xrefbib><pubid idtype="pmpid" link="fulltext">15972654</pubid></xrefbib></bibl><bibl id="B42"><title><p>Increased blood spermine levels decrease the cytotoxic activity of lymphokine-activated killer cells: a novel mechanism of cancer evasion</p></title><aug><au><snm>Kano</snm><fnm>Y</fnm></au><au><snm>Soda</snm><fnm>K</fnm></au><au><snm>Nakamura</snm><fnm>T</fnm></au><au><snm>Saitoh</snm><fnm>M</fnm></au><au><snm>Kawakami</snm><fnm>M</fnm></au><au><snm>Konishi</snm><fnm>F</fnm></au></aug><source>Cancer Immunol Immunother</source><pubdate>2007</pubdate><volume>56</volume><fpage>771</fpage><lpage>781</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1007/s00262-006-0229-4</pubid><pubid idtype="pmpid" link="fulltext">16972077</pubid></pubidlist></xrefbib></bibl><bibl id="B43"><title><p>Effect of alpha-difluoromethylornithine in lung metastases before and after surgery of primary adenocarcinoma tumors in mice</p></title><aug><au><snm>Klein</snm><fnm>S</fnm></au><au><snm>Miret</snm><fnm>JJ</fnm></au><au><snm>Algranati</snm><fnm>ID</fnm></au><au><snm>de Lustig</snm><fnm>ES</fnm></au></aug><source>Biol Cell</source><pubdate>1985</pubdate><volume>53</volume><fpage>33</fpage><lpage>36</lpage><xrefbib><pubid idtype="pmpid">3158365</pubid></xrefbib></bibl><bibl id="B44"><title><p>Effects of alpha-difluoromethylornithine and methylglyoxal bis(guanylhydrazone) on the growth of experimental renal adenocarcinoma in mice</p></title><aug><au><snm>Herr</snm><fnm>HW</fnm></au><au><snm>Kleinert</snm><fnm>EL</fnm></au><au><snm>Conti</snm><fnm>PS</fnm></au><au><snm>Burchenal</snm><fnm>JH</fnm></au><au><snm>Whitmore</snm><fnm>WF</fnm><suf>Jr</suf></au></aug><source>Cancer Res</source><pubdate>1984</pubdate><volume>44</volume><fpage>4382</fpage><lpage>4385</lpage><xrefbib><pubid idtype="pmpid" link="fulltext">6432312</pubid></xrefbib></bibl><bibl id="B45"><title><p>Successful treatment with DL-alpha-difluoromethylornithine in established human small cell variant lung carcinoma implants in athymic mice</p></title><aug><au><snm>Luk</snm><fnm>GD</fnm></au><au><snm>Abeloff</snm><fnm>MD</fnm></au><au><snm>Griffin</snm><fnm>CA</fnm></au><au><snm>Baylin</snm><fnm>SB</fnm></au></aug><source>Cancer Res</source><pubdate>1983</pubdate><volume>43</volume><fpage>4239</fpage><lpage>4243</lpage><xrefbib><pubid idtype="pmpid" link="fulltext">6409400</pubid></xrefbib></bibl><bibl id="B46"><title><p>Effects of alpha-difluoromethylornithine on the growth of experimental Wilms' tumor and renal adenocarcinoma</p></title><aug><au><snm>Kingsnorth</snm><fnm>AN</fnm></au><au><snm>McCann</snm><fnm>PP</fnm></au><au><snm>Diekema</snm><fnm>KA</fnm></au><au><snm>Ross</snm><fnm>JS</fnm></au><au><snm>Malt</snm><fnm>RA</fnm></au></aug><source>Cancer Res</source><pubdate>1983</pubdate><volume>43</volume><fpage>4031</fpage><lpage>4034</lpage><xrefbib><pubid idtype="pmpid" link="fulltext">6307502</pubid></xrefbib></bibl><bibl id="B47"><title><p>Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme</p></title><aug><au><snm>Prados</snm><fnm>MD</fnm></au><au><snm>Wara</snm><fnm>WM</fnm></au><au><snm>Sneed</snm><fnm>PK</fnm></au><au><snm>McDermott</snm><fnm>M</fnm></au><au><snm>Chang</snm><fnm>SM</fnm></au><au><snm>Rabbitt</snm><fnm>J</fnm></au><au><snm>Page</snm><fnm>M</fnm></au><au><snm>Malec</snm><fnm>M</fnm></au><au><snm>Davis</snm><fnm>RL</fnm></au><au><snm>Gutin</snm><fnm>PH</fnm></au><etal/></aug><source>Int J Radiat Oncol Biol Phys</source><pubdate>2001</pubdate><volume>49</volume><fpage>71</fpage><lpage>77</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1016/S0360-3016(00)01458-9</pubid><pubid idtype="pmpid" link="fulltext">11163499</pubid></pubidlist></xrefbib></bibl><bibl id="B48"><title><p>Randomized prospective phase III trial of difluoromethylornithine vs placebo in preventing recurrence of completely resected low risk superficial bladder cancer</p></title><aug><au><snm>Messing</snm><fnm>E</fnm></au><au><snm>Kim</snm><fnm>KM</fnm></au><au><snm>Sharkey</snm><fnm>F</fnm></au><au><snm>Schultz</snm><fnm>M</fnm></au><au><snm>Parnes</snm><fnm>H</fnm></au><au><snm>Kim</snm><fnm>D</fnm></au><au><snm>Saltzstein</snm><fnm>D</fnm></au><au><snm>Wilding</snm><fnm>G</fnm></au></aug><source>J Urol</source><pubdate>2006</pubdate><volume>176</volume><fpage>500</fpage><lpage>504</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1016/j.juro.2006.03.061</pubid><pubid idtype="pmpid" link="fulltext">16813878</pubid></pubidlist></xrefbib></bibl><bibl id="B49"><title><p>Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial</p></title><aug><au><snm>Meyskens</snm><fnm>FL</fnm><suf>Jr</suf></au><au><snm>McLaren</snm><fnm>CE</fnm></au><au><snm>Pelot</snm><fnm>D</fnm></au><au><snm>Fujikawa-Brooks</snm><fnm>S</fnm></au><au><snm>Carpenter</snm><fnm>PM</fnm></au><au><snm>Hawk</snm><fnm>E</fnm></au><au><snm>Kelloff</snm><fnm>G</fnm></au><au><snm>Lawson</snm><fnm>MJ</fnm></au><au><snm>Kidao</snm><fnm>J</fnm></au><au><snm>McCracken</snm><fnm>J</fnm></au><etal/></aug><source>Cancer Prev Res (Phila)</source><pubdate>2008</pubdate><volume>1</volume><fpage>32</fpage><lpage>38</lpage><xrefbib><pubid idtype="doi">10.1158/1940-6207.CAPR-08-0042</pubid></xrefbib></bibl><bibl id="B50"><title><p>Polyamine deprivation enhances antitumoral efficacy of chemotherapy</p></title><aug><au><snm>Quemener</snm><fnm>V</fnm></au><au><snm>Moulinoux</snm><fnm>JP</fnm></au><au><snm>Havouis</snm><fnm>R</fnm></au><au><snm>Seiler</snm><fnm>N</fnm></au></aug><source>Anticancer Res</source><pubdate>1992</pubdate><volume>12</volume><fpage>1447</fpage><lpage>1453</lpage><xrefbib><pubid idtype="pmpid">1444206</pubid></xrefbib></bibl><bibl id="B51"><title><p>Levels of rectal mucosal polyamines and prostaglandin E2 predict ability of DFMO and sulindac to prevent colorectal adenoma</p></title><aug><au><snm>Thompson</snm><fnm>PA</fnm></au><au><snm>Wertheim</snm><fnm>BC</fnm></au><au><snm>Zell</snm><fnm>JA</fnm></au><au><snm>Chen</snm><fnm>WP</fnm></au><au><snm>McLaren</snm><fnm>CE</fnm></au><au><snm>LaFleur</snm><fnm>BJ</fnm></au><au><snm>Meyskens</snm><fnm>FL</fnm></au><au><snm>Gerner</snm><fnm>EW</fnm></au></aug><source>Gastroenterology</source><pubdate>2010</pubdate><volume>139</volume><fpage>797</fpage><lpage>805</lpage><note>805 e791</note><xrefbib><pubidlist><pubid idtype="doi">10.1053/j.gastro.2010.06.005</pubid><pubid idtype="pmpid" link="fulltext">20538001</pubid></pubidlist></xrefbib></bibl><bibl id="B52"><title><p>Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas</p></title><aug><au><snm>Levin</snm><fnm>VA</fnm></au><au><snm>Hess</snm><fnm>KR</fnm></au><au><snm>Choucair</snm><fnm>A</fnm></au><au><snm>Flynn</snm><fnm>PJ</fnm></au><au><snm>Jaeckle</snm><fnm>KA</fnm></au><au><snm>Kyritsis</snm><fnm>AP</fnm></au><au><snm>Yung</snm><fnm>WK</fnm></au><au><snm>Prados</snm><fnm>MD</fnm></au><au><snm>Bruner</snm><fnm>JM</fnm></au><au><snm>Ictech</snm><fnm>S</fnm></au><etal/></aug><source>Clin Cancer Res</source><pubdate>2003</pubdate><volume>9</volume><fpage>981</fpage><lpage>990</lpage><xrefbib><pubid idtype="pmpid" link="fulltext">12631596</pubid></xrefbib></bibl><bibl id="B53"><title><p>Effects of polyamine depletion by alpha-difluoromethylornithine on in vitro and in vivo biological properties of 4T1 murine mammary cancer cells</p></title><aug><au><snm>Jun</snm><fnm>JY</fnm></au><au><snm>Griffith</snm><fnm>JW</fnm></au><au><snm>Bruggeman</snm><fnm>R</fnm></au><au><snm>Washington</snm><fnm>S</fnm></au><au><snm>Demers</snm><fnm>LM</fnm></au><au><snm>Verderame</snm><fnm>MF</fnm></au><au><snm>Manni</snm><fnm>A</fnm></au></aug><source>Breast Cancer Res Treat</source><pubdate>2008</pubdate><volume>107</volume><fpage>33</fpage><lpage>40</lpage><xrefbib><pubid idtype="pmpid" link="fulltext">17333337</pubid></xrefbib></bibl><bibl id="B54"><title><p>Effects of DL-alpha-difluoromethylornithine on the growth and metastasis of B16 melanoma in vivo</p></title><aug><au><snm>Kubota</snm><fnm>S</fnm></au><au><snm>Ohsawa</snm><fnm>N</fnm></au><au><snm>Takaku</snm><fnm>F</fnm></au></aug><source>Int J Cancer</source><pubdate>1987</pubdate><volume>39</volume><fpage>244</fpage><lpage>247</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1002/ijc.2910390220</pubid><pubid idtype="pmpid">3100460</pubid></pubidlist></xrefbib></bibl><bibl id="B55"><title><p>Effects of polyamine synthesis inhibitors on primary tumor features and metastatic capacity of human breast cancer cells</p></title><aug><au><snm>Manni</snm><fnm>A</fnm></au><au><snm>Washington</snm><fnm>S</fnm></au><au><snm>Hu</snm><fnm>X</fnm></au><au><snm>Griffith</snm><fnm>JW</fnm></au><au><snm>Bruggeman</snm><fnm>R</fnm></au><au><snm>Demers</snm><fnm>LM</fnm></au><au><snm>Mauger</snm><fnm>D</fnm></au><au><snm>Verderame</snm><fnm>MF</fnm></au></aug><source>Clin Exp Metastasis</source><pubdate>2005</pubdate><volume>22</volume><fpage>255</fpage><lpage>263</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1007/s10585-005-8480-1</pubid><pubid idtype="pmpid" link="fulltext">16158253</pubid></pubidlist></xrefbib></bibl><bibl id="B56"><title><p>Molecular basis of tumour metastasis</p></title><aug><au><snm>MacDonald</snm><fnm>NJ</fnm></au><au><snm>Steeg</snm><fnm>PS</fnm></au></aug><source>Cancer Surv</source><pubdate>1993</pubdate><volume>16</volume><fpage>175</fpage><lpage>199</lpage><xrefbib><pubid idtype="pmpid">7688661</pubid></xrefbib></bibl><bibl id="B57"><title><p>Tumor invasion and the extracellular matrix</p></title><aug><au><snm>Liotta</snm><fnm>LA</fnm></au><au><snm>Rao</snm><fnm>CN</fnm></au><au><snm>Barsky</snm><fnm>SH</fnm></au></aug><source>Lab Invest</source><pubdate>1983</pubdate><volume>49</volume><fpage>636</fpage><lpage>649</lpage><xrefbib><pubid idtype="pmpid">6317982</pubid></xrefbib></bibl><bibl id="B58"><title><p>Epithelial-mesenchymal transition: a cancer researcher's conceptual friend and foe</p></title><aug><au><snm>Klymkowsky</snm><fnm>MW</fnm></au><au><snm>Savagner</snm><fnm>P</fnm></au></aug><source>Am J Pathol</source><pubdate>2009</pubdate><volume>174</volume><fpage>1588</fpage><lpage>1593</lpage><xrefbib><pubidlist><pubid idtype="doi">10.2353/ajpath.2009.080545</pubid><pubid idtype="pmcid">2671246</pubid><pubid idtype="pmpid" link="fulltext">19342369</pubid></pubidlist></xrefbib></bibl><bibl id="B59"><title><p>Hypoxia signalling in cancer and approaches to enforce tumour regression</p></title><aug><au><snm>Pouyssegur</snm><fnm>J</fnm></au><au><snm>Dayan</snm><fnm>F</fnm></au><au><snm>Mazure</snm><fnm>NM</fnm></au></aug><source>Nature</source><pubdate>2006</pubdate><volume>441</volume><fpage>437</fpage><lpage>443</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1038/nature04871</pubid><pubid idtype="pmpid" link="fulltext">16724055</pubid></pubidlist></xrefbib></bibl><bibl id="B60"><title><p>Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects</p></title><aug><au><snm>Hockel</snm><fnm>M</fnm></au><au><snm>Vaupel</snm><fnm>P</fnm></au></aug><source>J Natl Cancer Inst</source><pubdate>2001</pubdate><volume>93</volume><fpage>266</fpage><lpage>276</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1093/jnci/93.4.266</pubid><pubid idtype="pmpid" link="fulltext">11181773</pubid></pubidlist></xrefbib></bibl><bibl id="B61"><title><p>Hypoxia--a key regulatory factor in tumour growth</p></title><aug><au><snm>Harris</snm><fnm>AL</fnm></au></aug><source>Nat Rev Cancer</source><pubdate>2002</pubdate><volume>2</volume><fpage>38</fpage><lpage>47</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1038/nrc704</pubid><pubid idtype="pmpid" link="fulltext">11902584</pubid></pubidlist></xrefbib></bibl><bibl id="B62"><title><p>Regulation of E-cadherin: does hypoxia initiate the metastatic cascade?</p></title><aug><au><snm>Beavon</snm><fnm>IR</fnm></au></aug><source>Mol Pathol</source><pubdate>1999</pubdate><volume>52</volume><fpage>179</fpage><lpage>188</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1136/mp.52.4.179</pubid><pubid idtype="pmcid">395697</pubid><pubid idtype="pmpid" link="fulltext">10694937</pubid></pubidlist></xrefbib></bibl><bibl id="B63"><title><p>Hypoxia facilitates tumour cell detachment by reducing expression of surface adhesion molecules and adhesion to extracellular matrices without loss of cell viability</p></title><aug><au><snm>Hasan</snm><fnm>NM</fnm></au><au><snm>Adams</snm><fnm>GE</fnm></au><au><snm>Joiner</snm><fnm>MC</fnm></au><au><snm>Marshall</snm><fnm>JF</fnm></au><au><snm>Hart</snm><fnm>IR</fnm></au></aug><source>Br J Cancer</source><pubdate>1998</pubdate><volume>77</volume><fpage>1799</fpage><lpage>1805</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1038/bjc.1998.299</pubid><pubid idtype="pmcid">2150343</pubid><pubid idtype="pmpid">9667649</pubid></pubidlist></xrefbib></bibl><bibl id="B64"><title><p>Involvement of polyamines in apoptosis of cardiac myoblasts in a model of simulated ischemia</p></title><aug><au><snm>Tantini</snm><fnm>B</fnm></au><au><snm>Fiumana</snm><fnm>E</fnm></au><au><snm>Cetrullo</snm><fnm>S</fnm></au><au><snm>Pignatti</snm><fnm>C</fnm></au><au><snm>Bonavita</snm><fnm>F</fnm></au><au><snm>Shantz</snm><fnm>LM</fnm></au><au><snm>Giordano</snm><fnm>E</fnm></au><au><snm>Muscari</snm><fnm>C</fnm></au><au><snm>Flamigni</snm><fnm>F</fnm></au><au><snm>Guarnieri</snm><fnm>C</fnm></au><etal/></aug><source>J Mol Cell Cardiol</source><pubdate>2006</pubdate><volume>40</volume><fpage>775</fpage><lpage>782</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1016/j.yjmcc.2006.03.002</pubid><pubid idtype="pmpid" link="fulltext">16678846</pubid></pubidlist></xrefbib></bibl><bibl id="B65"><title><p>Multiple polyamine transport pathways in cultured pulmonary artery smooth muscle cells: regulation by hypoxia</p></title><aug><au><snm>Aziz</snm><fnm>SM</fnm></au><au><snm>Olson</snm><fnm>JW</fnm></au><au><snm>Gillespie</snm><fnm>MN</fnm></au></aug><source>Am J Respir Cell Mol Biol</source><pubdate>1994</pubdate><volume>10</volume><fpage>160</fpage><lpage>166</lpage><xrefbib><pubid idtype="pmpid" link="fulltext">8110472</pubid></xrefbib></bibl><bibl id="B66"><title><p>Spermine accelerates hypoxia-initiated cancer cell migration</p></title><aug><au><snm>Tsujinaka</snm><fnm>S</fnm></au><au><snm>Soda</snm><fnm>K</fnm></au><au><snm>Kano</snm><fnm>Y</fnm></au><au><snm>Konishi</snm><fnm>F</fnm></au></aug><source>Int J Oncol</source><pubdate>2011</pubdate><volume>38</volume><fpage>305</fpage><lpage>312</lpage><xrefbib><pubid idtype="pmpid" link="fulltext">21132262</pubid></xrefbib></bibl><bibl id="B67"><title><p>CD44 and CD44v6 downregulation in clinical prostatic carcinoma: relation to Gleason grade and cytoarchitecture</p></title><aug><au><snm>De Marzo</snm><fnm>AM</fnm></au><au><snm>Bradshaw</snm><fnm>C</fnm></au><au><snm>Sauvageot</snm><fnm>J</fnm></au><au><snm>Epstein</snm><fnm>JI</fnm></au><au><snm>Miller</snm><fnm>GJ</fnm></au></aug><source>Prostate</source><pubdate>1998</pubdate><volume>34</volume><fpage>162</fpage><lpage>168</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1002/(SICI)1097-0045(19980215)34:3&lt;162::AID-PROS2&gt;3.0.CO;2-K</pubid><pubid idtype="pmpid" link="fulltext">9492843</pubid></pubidlist></xrefbib></bibl><bibl id="B68"><title><p>Decreased levels of CD44 protein and mRNA in prostate carcinoma. Correlation with tumor grade and ploidy</p></title><aug><au><snm>Kallakury</snm><fnm>BV</fnm></au><au><snm>Yang</snm><fnm>F</fnm></au><au><snm>Figge</snm><fnm>J</fnm></au><au><snm>Smith</snm><fnm>KE</fnm></au><au><snm>Kausik</snm><fnm>SJ</fnm></au><au><snm>Tacy</snm><fnm>NJ</fnm></au><au><snm>Fisher</snm><fnm>HA</fnm></au><au><snm>Kaufman</snm><fnm>R</fnm></au><au><snm>Figge</snm><fnm>H</fnm></au><au><snm>Ross</snm><fnm>JS</fnm></au></aug><source>Cancer</source><pubdate>1996</pubdate><volume>78</volume><fpage>1461</fpage><lpage>1469</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1002/(SICI)1097-0142(19961001)78:7&lt;1461::AID-CNCR13&gt;3.0.CO;2-Y</pubid><pubid idtype="pmpid">8839552</pubid></pubidlist></xrefbib></bibl><bibl id="B69"><title><p>Antimetastatic activity of DL-alpha-difluoromethylornithine, an inhibitor of polyamine biosynthesis, in mice</p></title><aug><au><snm>Sunkara</snm><fnm>PS</fnm></au><au><snm>Rosenberger</snm><fnm>AL</fnm></au></aug><source>Cancer Res</source><pubdate>1987</pubdate><volume>47</volume><fpage>933</fpage><lpage>935</lpage><xrefbib><pubid idtype="pmpid" link="fulltext">3100031</pubid></xrefbib></bibl><bibl id="B70"><title><p>Matrix metalloproteinases as stromal effectors of human carcinoma progression: therapeutic implications</p></title><aug><au><snm>Basset</snm><fnm>P</fnm></au><au><snm>Okada</snm><fnm>A</fnm></au><au><snm>Chenard</snm><fnm>MP</fnm></au><au><snm>Kannan</snm><fnm>R</fnm></au><au><snm>Stoll</snm><fnm>I</fnm></au><au><snm>Anglard</snm><fnm>P</fnm></au><au><snm>Bellocq</snm><fnm>JP</fnm></au><au><snm>Rio</snm><fnm>MC</fnm></au></aug><source>Matrix Biol</source><pubdate>1997</pubdate><volume>15</volume><fpage>535</fpage><lpage>541</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1016/S0945-053X(97)90028-7</pubid><pubid idtype="pmpid">9138286</pubid></pubidlist></xrefbib></bibl><bibl id="B71"><title><p>Matrix metalloproteinases: biologic activity and clinical implications</p></title><aug><au><snm>Nelson</snm><fnm>AR</fnm></au><au><snm>Fingleton</snm><fnm>B</fnm></au><au><snm>Rothenberg</snm><fnm>ML</fnm></au><au><snm>Matrisian</snm><fnm>LM</fnm></au></aug><source>J Clin Oncol</source><pubdate>2000</pubdate><volume>18</volume><fpage>1135</fpage><lpage>1149</lpage><xrefbib><pubid idtype="pmpid" link="fulltext">10694567</pubid></xrefbib></bibl><bibl id="B72"><title><p>Matrix metalloproteinases: regulators of the tumor microenvironment</p></title><aug><au><snm>Kessenbrock</snm><fnm>K</fnm></au><au><snm>Plaks</snm><fnm>V</fnm></au><au><snm>Werb</snm><fnm>Z</fnm></au></aug><source>Cell</source><pubdate>2010</pubdate><volume>141</volume><fpage>52</fpage><lpage>67</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1016/j.cell.2010.03.015</pubid><pubid idtype="pmcid">2862057</pubid><pubid idtype="pmpid" link="fulltext">20371345</pubid></pubidlist></xrefbib></bibl><bibl id="B73"><title><p>Tumor microenvironment and progression</p></title><aug><au><snm>Dvorak</snm><fnm>HF</fnm></au><au><snm>Weaver</snm><fnm>VM</fnm></au><au><snm>Tlsty</snm><fnm>TD</fnm></au><au><snm>Bergers</snm><fnm>G</fnm></au></aug><source>J Surg Oncol</source><pubdate>2011</pubdate><volume>103</volume><fpage>468</fpage><lpage>474</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1002/jso.21709</pubid><pubid idtype="pmpid" link="fulltext">21480238</pubid></pubidlist></xrefbib></bibl><bibl id="B74"><title><p>Ornithine decarboxylase overexpression in mouse 10T1/2 fibroblasts: cellular transformation and invasion</p></title><aug><au><snm>Kubota</snm><fnm>S</fnm></au><au><snm>Kiyosawa</snm><fnm>H</fnm></au><au><snm>Nomura</snm><fnm>Y</fnm></au><au><snm>Yamada</snm><fnm>T</fnm></au><au><snm>Seyama</snm><fnm>Y</fnm></au></aug><source>J Natl Cancer Inst</source><pubdate>1997</pubdate><volume>89</volume><fpage>567</fpage><lpage>571</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1093/jnci/89.8.567</pubid><pubid idtype="pmpid" link="fulltext">9106645</pubid></pubidlist></xrefbib></bibl><bibl id="B75"><title><p>Putrescine-dependent invasive capacity of rat ascites hepatoma cells</p></title><aug><au><snm>Ashida</snm><fnm>Y</fnm></au><au><snm>Kido</snm><fnm>J</fnm></au><au><snm>Kinoshita</snm><fnm>F</fnm></au><au><snm>Nishino</snm><fnm>M</fnm></au><au><snm>Shinkai</snm><fnm>K</fnm></au><au><snm>Akedo</snm><fnm>H</fnm></au><au><snm>Inoue</snm><fnm>H</fnm></au></aug><source>Cancer Res</source><pubdate>1992</pubdate><volume>52</volume><fpage>5313</fpage><lpage>5316</lpage><xrefbib><pubid idtype="pmpid" link="fulltext">1394136</pubid></xrefbib></bibl><bibl id="B76"><title><p>Polyamine-dependent expression of the matrix metalloproteinase matrilysin in a human colon cancer-derived cell line</p></title><aug><au><snm>Wallon</snm><fnm>UM</fnm></au><au><snm>Shassetz</snm><fnm>LR</fnm></au><au><snm>Cress</snm><fnm>AE</fnm></au><au><snm>Bowden</snm><fnm>GT</fnm></au><au><snm>Gerner</snm><fnm>EW</fnm></au></aug><source>Mol Carcinog</source><pubdate>1994</pubdate><volume>11</volume><fpage>138</fpage><lpage>144</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1002/mc.2940110304</pubid><pubid idtype="pmpid">7945802</pubid></pubidlist></xrefbib></bibl><bibl id="B77"><title><p>Inhibitors of polyamine biosynthesis decrease the expression of the metalloproteases meprin alpha and MMP-7 in hormone-independent human breast cancer cells</p></title><aug><au><snm>Matters</snm><fnm>GL</fnm></au><au><snm>Manni</snm><fnm>A</fnm></au><au><snm>Bond</snm><fnm>JS</fnm></au></aug><source>Clin Exp Metastasis</source><pubdate>2005</pubdate><volume>22</volume><fpage>331</fpage><lpage>339</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1007/s10585-005-0660-5</pubid><pubid idtype="pmpid" link="fulltext">16170669</pubid></pubidlist></xrefbib></bibl><bibl id="B78"><title><p>Human ornithine decarboxylase-overproducing NIH3T3 cells induce rapidly growing, highly vascularized tumors in nude mice</p></title><aug><au><snm>Auvinen</snm><fnm>M</fnm></au><au><snm>Laine</snm><fnm>A</fnm></au><au><snm>Paasinen-Sohns</snm><fnm>A</fnm></au><au><snm>Kangas</snm><fnm>A</fnm></au><au><snm>Kangas</snm><fnm>L</fnm></au><au><snm>Saksela</snm><fnm>O</fnm></au><au><snm>Andersson</snm><fnm>LC</fnm></au><au><snm>Holtta</snm><fnm>E</fnm></au></aug><source>Cancer Res</source><pubdate>1997</pubdate><volume>57</volume><fpage>3016</fpage><lpage>3025</lpage><xrefbib><pubid idtype="pmpid" link="fulltext">9230217</pubid></xrefbib></bibl><bibl id="B79"><title><p>Tumor angiogenesis and polyamines: alpha-difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase, inhibits B16 melanoma-induced angiogenesis in ovo and the proliferation of vascular endothelial cells in vitro</p></title><aug><au><snm>Takigawa</snm><fnm>M</fnm></au><au><snm>Enomoto</snm><fnm>M</fnm></au><au><snm>Nishida</snm><fnm>Y</fnm></au><au><snm>Pan</snm><fnm>HO</fnm></au><au><snm>Kinoshita</snm><fnm>A</fnm></au><au><snm>Suzuki</snm><fnm>F</fnm></au></aug><source>Cancer Res</source><pubdate>1990</pubdate><volume>50</volume><fpage>4131</fpage><lpage>4138</lpage><xrefbib><pubid idtype="pmpid" link="fulltext">1693880</pubid></xrefbib></bibl><bibl id="B80"><title><p>Deficient strongly adherent monocytes in the peripheral blood of cancer patients</p></title><aug><au><snm>Hersh</snm><fnm>EM</fnm></au><au><snm>Gschwind</snm><fnm>C</fnm></au><au><snm>Morris</snm><fnm>DL</fnm></au><au><snm>Murphy</snm><fnm>S</fnm></au></aug><source>Cancer Immunol Immunother</source><pubdate>1982</pubdate><volume>14</volume><fpage>105</fpage><lpage>109</lpage><xrefbib><pubid idtype="pmpid">6965225</pubid></xrefbib></bibl><bibl id="B81"><title><p>Tube leukocyte adherence inhibition assay for the detection of anti-tumor immunity. I. Monocyte is the reactive cell</p></title><aug><au><snm>Grosser</snm><fnm>N</fnm></au><au><snm>Marti</snm><fnm>JH</fnm></au><au><snm>Proctor</snm><fnm>JW</fnm></au><au><snm>Thomson</snm><fnm>DM</fnm></au></aug><source>Int J Cancer</source><pubdate>1976</pubdate><volume>18</volume><fpage>39</fpage><lpage>47</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1002/ijc.2910180107</pubid><pubid idtype="pmpid">1084863</pubid></pubidlist></xrefbib></bibl><bibl id="B82"><title><p>Predictive value of tube leukocyte adherence inhibition (LAI) assay for breast, colorectal, stomach and pancreatic cancer</p></title><aug><au><snm>MacFarlane</snm><fnm>JK</fnm></au><au><snm>Thomson</snm><fnm>DM</fnm></au><au><snm>Phelan</snm><fnm>K</fnm></au><au><snm>Shenouda</snm><fnm>G</fnm></au><au><snm>Scanzano</snm><fnm>R</fnm></au></aug><source>Cancer</source><pubdate>1982</pubdate><volume>49</volume><fpage>1185</fpage><lpage>1193</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1002/1097-0142(19820315)49:6&lt;1185::AID-CNCR2820490620&gt;3.0.CO;2-E</pubid><pubid idtype="pmpid">7037158</pubid></pubidlist></xrefbib></bibl><bibl id="B83"><title><p>Reduction in cytokine production in colorectal cancer patients: association with stage and reversal by resection</p></title><aug><au><snm>Heriot</snm><fnm>AG</fnm></au><au><snm>Marriott</snm><fnm>JB</fnm></au><au><snm>Cookson</snm><fnm>S</fnm></au><au><snm>Kumar</snm><fnm>D</fnm></au><au><snm>Dalgleish</snm><fnm>AG</fnm></au></aug><source>Br J Cancer</source><pubdate>2000</pubdate><volume>82</volume><fpage>1009</fpage><lpage>1012</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1054/bjoc.1999.1034</pubid><pubid idtype="pmcid">2374422</pubid><pubid idtype="pmpid" link="fulltext">10737381</pubid></pubidlist></xrefbib></bibl><bibl id="B84"><title><p>Immunological variations in women suffering from ovarian cancer. Influence of radical surgical treatment</p></title><aug><au><snm>Rampone</snm><fnm>B</fnm></au><au><snm>Rampone</snm><fnm>A</fnm></au><au><snm>Tirabasso</snm><fnm>S</fnm></au><au><snm>Panariello</snm><fnm>S</fnm></au><au><snm>Rampone</snm><fnm>N</fnm></au></aug><source>Minerva Ginecol</source><pubdate>2001</pubdate><volume>53</volume><fpage>116</fpage><lpage>119</lpage><xrefbib><pubid idtype="pmpid">11526704</pubid></xrefbib></bibl><bibl id="B85"><title><p>Decreased interleukin-2 production in patients with gastrointestinal cancer</p></title><aug><au><snm>Monson</snm><fnm>JR</fnm></au><au><snm>Ramsden</snm><fnm>C</fnm></au><au><snm>Guillou</snm><fnm>PJ</fnm></au></aug><source>Br J Surg</source><pubdate>1986</pubdate><volume>73</volume><fpage>483</fpage><lpage>486</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1002/bjs.1800730620</pubid><pubid idtype="pmpid">3487366</pubid></pubidlist></xrefbib></bibl><bibl id="B86"><title><p>Depressed lymphokine activated killer cell activity in mycosis fungoides. A possible marker for aggressive disease</p></title><aug><au><snm>Wood</snm><fnm>NL</fnm></au><au><snm>Kitces</snm><fnm>EN</fnm></au><au><snm>Blaylock</snm><fnm>WK</fnm></au></aug><source>Arch Dermatol</source><pubdate>1990</pubdate><volume>126</volume><fpage>907</fpage><lpage>913</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1001/archderm.126.7.907</pubid><pubid idtype="pmpid" link="fulltext">2360838</pubid></pubidlist></xrefbib></bibl><bibl id="B87"><title><p>Reduced LAK cytotoxicity of peripheral blood mononuclear cells in patients with bladder cancer: decreased LAK cytotoxicity caused by a low incidence of CD56+ and CD57+ mononuclear blood cells</p></title><aug><au><snm>Hermann</snm><fnm>GG</fnm></au><au><snm>Petersen</snm><fnm>KR</fnm></au><au><snm>Steven</snm><fnm>K</fnm></au><au><snm>Zeuthen</snm><fnm>J</fnm></au></aug><source>J Clin Immunol</source><pubdate>1990</pubdate><volume>10</volume><fpage>311</fpage><lpage>320</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1007/BF00917476</pubid><pubid idtype="pmpid">1707414</pubid></pubidlist></xrefbib></bibl><bibl id="B88"><title><p>Natural killer (NK) and lymphokine-activated killer (LAK) cell functions from healthy dogs and 29 dogs with a variety of spontaneous neoplasms</p></title><aug><au><snm>Funk</snm><fnm>J</fnm></au><au><snm>Schmitz</snm><fnm>G</fnm></au><au><snm>Failing</snm><fnm>K</fnm></au><au><snm>Burkhardt</snm><fnm>E</fnm></au></aug><source>Cancer Immunol Immunother</source><pubdate>2005</pubdate><volume>54</volume><fpage>87</fpage><lpage>92</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1007/s00262-004-0555-3</pubid><pubid idtype="pmpid">15693143</pubid></pubidlist></xrefbib></bibl><bibl id="B89"><title><p>Cellular immune defects in patients with melanoma involving interleukin-2-activated lymphocyte cytotoxicity and a serum suppressor factor</p></title><aug><au><snm>Balch</snm><fnm>CM</fnm></au><au><snm>Itoh</snm><fnm>K</fnm></au><au><snm>Tilden</snm><fnm>AB</fnm></au></aug><source>Surgery</source><pubdate>1985</pubdate><volume>98</volume><fpage>151</fpage><lpage>157</lpage><xrefbib><pubid idtype="pmpid">3875156</pubid></xrefbib></bibl><bibl id="B90"><title><p>Inhibition of interleukin 2 production by factors released from tumor cells</p></title><aug><au><snm>Hersey</snm><fnm>P</fnm></au><au><snm>Bindon</snm><fnm>C</fnm></au><au><snm>Czerniecki</snm><fnm>M</fnm></au><au><snm>Spurling</snm><fnm>A</fnm></au><au><snm>Wass</snm><fnm>J</fnm></au><au><snm>McCarthy</snm><fnm>WH</fnm></au></aug><source>J Immunol</source><pubdate>1983</pubdate><volume>131</volume><fpage>2837</fpage><lpage>2842</lpage><xrefbib><pubid idtype="pmpid" link="fulltext">6605993</pubid></xrefbib></bibl><bibl id="B91"><title><p>Modulation of TcR/CD3-zeta chain expression by a circulating factor derived from ovarian cancer patients</p></title><aug><au><snm>Taylor</snm><fnm>DD</fnm></au><au><snm>Bender</snm><fnm>DP</fnm></au><au><snm>Gercel-Taylor</snm><fnm>C</fnm></au><au><snm>Stanson</snm><fnm>J</fnm></au><au><snm>Whiteside</snm><fnm>TL</fnm></au></aug><source>Br J Cancer</source><pubdate>2001</pubdate><volume>84</volume><fpage>1624</fpage><lpage>1629</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1054/bjoc.2001.1847</pubid><pubid idtype="pmcid">2363678</pubid><pubid idtype="pmpid" link="fulltext">11401315</pubid></pubidlist></xrefbib></bibl><bibl id="B92"><title><p>Synthetic polyamines added to cultures containing bovine sera reversibly inhibit in vitro parameters of immunity</p></title><aug><au><snm>Byrd</snm><fnm>WJ</fnm></au><au><snm>Jacobs</snm><fnm>DM</fnm></au><au><snm>Amoss</snm><fnm>MS</fnm></au></aug><source>Nature</source><pubdate>1977</pubdate><volume>267</volume><fpage>621</fpage><lpage>623</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1038/267621a0</pubid><pubid idtype="pmpid">141619</pubid></pubidlist></xrefbib></bibl><bibl id="B93"><title><p>Polyamine deprivation prevents the development of tumour-induced immune suppression</p></title><aug><au><snm>Chamaillard</snm><fnm>L</fnm></au><au><snm>Catros-Quemener</snm><fnm>V</fnm></au><au><snm>Delcros</snm><fnm>JG</fnm></au><au><snm>Bansard</snm><fnm>JY</fnm></au><au><snm>Havouis</snm><fnm>R</fnm></au><au><snm>Desury</snm><fnm>D</fnm></au><au><snm>Commeurec</snm><fnm>A</fnm></au><au><snm>Genetet</snm><fnm>N</fnm></au><au><snm>Moulinoux</snm><fnm>JP</fnm></au></aug><source>Br J Cancer</source><pubdate>1997</pubdate><volume>76</volume><fpage>365</fpage><lpage>370</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1038/bjc.1997.391</pubid><pubid idtype="pmcid">2224072</pubid><pubid idtype="pmpid">9252204</pubid></pubidlist></xrefbib></bibl><bibl id="B94"><title><p>Highly oncolytic adherent lymphocytes: therapeutic relevance for leukemia</p></title><aug><au><snm>Lotzova</snm><fnm>E</fnm></au><au><snm>Savary</snm><fnm>CA</fnm></au><au><snm>Totpal</snm><fnm>K</fnm></au><au><snm>Schachner</snm><fnm>J</fnm></au><au><snm>Lichtiger</snm><fnm>B</fnm></au><au><snm>McCredie</snm><fnm>KB</fnm></au><au><snm>Freireich</snm><fnm>EJ</fnm></au></aug><source>Leuk Res</source><pubdate>1991</pubdate><volume>15</volume><fpage>245</fpage><lpage>254</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1016/0145-2126(91)90127-F</pubid><pubid idtype="pmpid">2030606</pubid></pubidlist></xrefbib></bibl><bibl id="B95"><title><p>Polyamine concentrations in pancreatic tissue, serum, and urine of patients with pancreatic cancer</p></title><aug><au><snm>Loser</snm><fnm>C</fnm></au><au><snm>Folsch</snm><fnm>UR</fnm></au><au><snm>Paprotny</snm><fnm>C</fnm></au><au><snm>Creutzfeldt</snm><fnm>W</fnm></au></aug><source>Pancreas</source><pubdate>1990</pubdate><volume>5</volume><fpage>119</fpage><lpage>127</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1097/00006676-199003000-00001</pubid><pubid idtype="pmpid" link="fulltext">2315288</pubid></pubidlist></xrefbib></bibl><bibl id="B96"><title><p>Erythrocyte-binding polyamine as a tumor growth marker for human hepatocellular carcinoma</p></title><aug><au><snm>Nishiguchi</snm><fnm>S</fnm></au><au><snm>Tamori</snm><fnm>A</fnm></au><au><snm>Koh</snm><fnm>N</fnm></au><au><snm>Fujimoto</snm><fnm>S</fnm></au><au><snm>Takeda</snm><fnm>T</fnm></au><au><snm>Shiomi</snm><fnm>S</fnm></au><au><snm>Oka</snm><fnm>H</fnm></au><au><snm>Yano</snm><fnm>Y</fnm></au><au><snm>Otani</snm><fnm>S</fnm></au><au><snm>Kuroki</snm><fnm>T</fnm></au></aug><source>Hepatogastroenterology</source><pubdate>2002</pubdate><volume>49</volume><fpage>504</fpage><lpage>507</lpage><xrefbib><pubid idtype="pmpid">11995483</pubid></xrefbib></bibl><bibl id="B97"><title><p>Serum polyamine alterations in surgical patients with colorectal carcinoma</p></title><aug><au><snm>Nishioka</snm><fnm>K</fnm></au><au><snm>Romsdahl</snm><fnm>MM</fnm></au><au><snm>McMurtrey</snm><fnm>MJ</fnm></au></aug><source>J Surg Oncol</source><pubdate>1977</pubdate><volume>9</volume><fpage>555</fpage><lpage>562</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1002/jso.2930090605</pubid><pubid idtype="pmpid">592854</pubid></pubidlist></xrefbib></bibl><bibl id="B98"><title><p>Transport and metabolism of polyamines in human lymphocytes</p></title><aug><au><snm>Colombatto</snm><fnm>S</fnm></au><au><snm>Fasulo</snm><fnm>L</fnm></au><au><snm>Fulgosi</snm><fnm>B</fnm></au><au><snm>Grillo</snm><fnm>MA</fnm></au></aug><source>Int J Biochem</source><pubdate>1990</pubdate><volume>22</volume><fpage>489</fpage><lpage>492</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1016/0020-711X(90)90262-2</pubid><pubid idtype="pmpid">2161357</pubid></pubidlist></xrefbib></bibl><bibl id="B99"><title><p>Polyamine metabolism and uptake during Phaseolus vulgaris lectin, PHA-induced growth of rat small intestine</p></title><aug><au><snm>Bardocz</snm><fnm>S</fnm></au><au><snm>Grant</snm><fnm>G</fnm></au><au><snm>Brown</snm><fnm>DS</fnm></au><au><snm>Ewen</snm><fnm>SW</fnm></au><au><snm>Nevison</snm><fnm>I</fnm></au><au><snm>Pusztai</snm><fnm>A</fnm></au></aug><source>Digestion</source><pubdate>1990</pubdate><volume>46</volume><issue>Suppl 2</issue><fpage>360</fpage><lpage>366</lpage><xrefbib><pubid idtype="pmpid">2262068</pubid></xrefbib></bibl><bibl id="B100"><title><p>Distribution of spermidine and spermine in blood from cystic fibrosis patients and control subjects</p></title><aug><au><snm>Cohen</snm><fnm>LF</fnm></au><au><snm>Lundgren</snm><fnm>DW</fnm></au><au><snm>Farrell</snm><fnm>PM</fnm></au></aug><source>Blood</source><pubdate>1976</pubdate><volume>48</volume><fpage>469</fpage><lpage>475</lpage><xrefbib><pubid idtype="pmpid" link="fulltext">953366</pubid></xrefbib></bibl><bibl id="B101"><title><p>Functional heterogeneity of Leu 19"bright"+ and Leu 19"dim"+ lymphokine-activated killer cells</p></title><aug><au><snm>Ellis</snm><fnm>TM</fnm></au><au><snm>Fisher</snm><fnm>RI</fnm></au></aug><source>J Immunol</source><pubdate>1989</pubdate><volume>142</volume><fpage>2949</fpage><lpage>2954</lpage><xrefbib><pubid idtype="pmpid" link="fulltext">2467946</pubid></xrefbib></bibl><bibl id="B102"><title><p>Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and leu19 antigens but negative expression of CD16 antigens</p></title><aug><au><snm>Weil-Hillman</snm><fnm>G</fnm></au><au><snm>Fisch</snm><fnm>P</fnm></au><au><snm>Prieve</snm><fnm>AF</fnm></au><au><snm>Sosman</snm><fnm>JA</fnm></au><au><snm>Hank</snm><fnm>JA</fnm></au><au><snm>Sondel</snm><fnm>PM</fnm></au></aug><source>Cancer Res</source><pubdate>1989</pubdate><volume>49</volume><fpage>3680</fpage><lpage>3688</lpage><xrefbib><pubid idtype="pmpid" link="fulltext">2471587</pubid></xrefbib></bibl><bibl id="B103"><title><p>Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2</p></title><aug><au><snm>Mule</snm><fnm>JJ</fnm></au><au><snm>Shu</snm><fnm>S</fnm></au><au><snm>Schwarz</snm><fnm>SL</fnm></au><au><snm>Rosenberg</snm><fnm>SA</fnm></au></aug><source>Science</source><pubdate>1984</pubdate><volume>225</volume><fpage>1487</fpage><lpage>1489</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1126/science.6332379</pubid><pubid idtype="pmpid" link="fulltext">6332379</pubid></pubidlist></xrefbib></bibl><bibl id="B104"><title><p>Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2</p></title><aug><au><snm>Rosenberg</snm><fnm>SA</fnm></au><au><snm>Mule</snm><fnm>JJ</fnm></au><au><snm>Spiess</snm><fnm>PJ</fnm></au><au><snm>Reichert</snm><fnm>CM</fnm></au><au><snm>Schwarz</snm><fnm>SL</fnm></au></aug><source>J Exp Med</source><pubdate>1985</pubdate><volume>161</volume><fpage>1169</fpage><lpage>1188</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1084/jem.161.5.1169</pubid><pubid idtype="pmcid">2187617</pubid><pubid idtype="pmpid">3886826</pubid></pubidlist></xrefbib></bibl><bibl id="B105"><title><p>Spermine and spermidine induce some of the immune suppression observed in cancer patients</p></title><aug><au><snm>Soda</snm><fnm>K</fnm></au><au><snm>Kano</snm><fnm>Y</fnm></au><au><snm>Nakamura</snm><fnm>T</fnm></au><au><snm>Kawakami</snm><fnm>M</fnm></au><au><snm>Konishi</snm><fnm>F</fnm></au></aug><source>Annals of Cancer Research and Therapy</source><pubdate>2003</pubdate><volume>11</volume><fpage>243</fpage><lpage>253</lpage></bibl><bibl id="B106"><title><p>Spermine inhibits proinflammatory cytokine synthesis in human mononuclear cells: a counterregulatory mechanism that restrains the immune response</p></title><aug><au><snm>Zhang</snm><fnm>M</fnm></au><au><snm>Caragine</snm><fnm>T</fnm></au><au><snm>Wang</snm><fnm>H</fnm></au><au><snm>Cohen</snm><fnm>PS</fnm></au><au><snm>Botchkina</snm><fnm>G</fnm></au><au><snm>Soda</snm><fnm>K</fnm></au><au><snm>Bianchi</snm><fnm>M</fnm></au><au><snm>Ulrich</snm><fnm>P</fnm></au><au><snm>Cerami</snm><fnm>A</fnm></au><au><snm>Sherry</snm><fnm>B</fnm></au><au><snm>Tracey</snm><fnm>KJ</fnm></au></aug><source>J Exp Med</source><pubdate>1997</pubdate><volume>185</volume><fpage>1759</fpage><lpage>1768</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1084/jem.185.10.1759</pubid><pubid idtype="pmcid">2196317</pubid><pubid idtype="pmpid" link="fulltext">9151701</pubid></pubidlist></xrefbib></bibl><bibl id="B107"><title><p>Spermine differentially regulates the production of interleukin-12 p40 and interleukin-10 and suppresses the release of the T helper 1 cytokine interferon-gamma</p></title><aug><au><snm>Hasko</snm><fnm>G</fnm></au><au><snm>Kuhel</snm><fnm>DG</fnm></au><au><snm>Marton</snm><fnm>A</fnm></au><au><snm>Nemeth</snm><fnm>ZH</fnm></au><au><snm>Deitch</snm><fnm>EA</fnm></au><au><snm>Szabo</snm><fnm>C</fnm></au></aug><source>Shock</source><pubdate>2000</pubdate><volume>14</volume><fpage>144</fpage><lpage>149</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1097/00024382-200014020-00012</pubid><pubid idtype="pmpid">10947158</pubid></pubidlist></xrefbib></bibl><bibl id="B108"><title><p>The effect of alpha-difluoromethylornithine, an inhibitor of polyamine biosynthesis, on mitogen-induced interleukin 2 production</p></title><aug><au><snm>Bowlin</snm><fnm>TL</fnm></au><au><snm>McKown</snm><fnm>BJ</fnm></au><au><snm>Sunkara</snm><fnm>PS</fnm></au></aug><source>Immunopharmacology</source><pubdate>1987</pubdate><volume>13</volume><fpage>143</fpage><lpage>147</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1016/0162-3109(87)90051-8</pubid><pubid idtype="pmpid">3110101</pubid></pubidlist></xrefbib></bibl><bibl id="B109"><title><p>Polyamine deprivation stimulates natural killer cell activity in cancerous mice</p></title><aug><au><snm>Chamaillard</snm><fnm>L</fnm></au><au><snm>Quemener</snm><fnm>V</fnm></au><au><snm>Havouis</snm><fnm>R</fnm></au><au><snm>Moulinoux</snm><fnm>JP</fnm></au></aug><source>Anticancer Res</source><pubdate>1993</pubdate><volume>13</volume><fpage>1027</fpage><lpage>1033</lpage><xrefbib><pubid idtype="pmpid">8352521</pubid></xrefbib></bibl><bibl id="B110"><title><p>An endotoxin-induced serum factor that causes necrosis of tumors</p></title><aug><au><snm>Carswell</snm><fnm>EA</fnm></au><au><snm>Old</snm><fnm>LJ</fnm></au><au><snm>Kassel</snm><fnm>RL</fnm></au><au><snm>Green</snm><fnm>S</fnm></au><au><snm>Fiore</snm><fnm>N</fnm></au><au><snm>Williamson</snm><fnm>B</fnm></au></aug><source>Proc Natl Acad Sci USA</source><pubdate>1975</pubdate><volume>72</volume><fpage>3666</fpage><lpage>3670</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1073/pnas.72.9.3666</pubid><pubid idtype="pmcid">433057</pubid><pubid idtype="pmpid">1103152</pubid></pubidlist></xrefbib></bibl><bibl id="B111"><title><p>Leukocyte function-associated antigen 1 is an activation molecule for human T cells</p></title><aug><au><snm>Wacholtz</snm><fnm>MC</fnm></au><au><snm>Patel</snm><fnm>SS</fnm></au><au><snm>Lipsky</snm><fnm>PE</fnm></au></aug><source>J Exp Med</source><pubdate>1989</pubdate><volume>170</volume><fpage>431</fpage><lpage>448</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1084/jem.170.2.431</pubid><pubid idtype="pmcid">2189396</pubid><pubid idtype="pmpid">2569026</pubid></pubidlist></xrefbib></bibl><bibl id="B112"><title><p>The LFA-1/ICAM cell adhesion pathway is involved in tumor-cell lysis mediated by bispecific monoclonal-antibody-targeted T lymphocytes</p></title><aug><au><snm>Ferrini</snm><fnm>S</fnm></au><au><snm>Sforzini</snm><fnm>S</fnm></au><au><snm>Cambiaggi</snm><fnm>A</fnm></au><au><snm>Poggi</snm><fnm>A</fnm></au><au><snm>Meazza</snm><fnm>R</fnm></au><au><snm>Canevari</snm><fnm>S</fnm></au><au><snm>Colnaghi</snm><fnm>MI</fnm></au><au><snm>Moretta</snm><fnm>L</fnm></au></aug><source>Int J Cancer</source><pubdate>1994</pubdate><volume>56</volume><fpage>846</fpage><lpage>852</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1002/ijc.2910560616</pubid><pubid idtype="pmpid">7907079</pubid></pubidlist></xrefbib></bibl><bibl id="B113"><title><p>Effect of polyamine deprivation on the survival of intracranial glioblastoma bearing rats</p></title><aug><au><snm>Sarhan</snm><fnm>S</fnm></au><au><snm>Weibel</snm><fnm>M</fnm></au><au><snm>Seiler</snm><fnm>N</fnm></au></aug><source>Anticancer Res</source><pubdate>1991</pubdate><volume>11</volume><fpage>987</fpage><lpage>992</lpage><xrefbib><pubid idtype="pmpid">2064355</pubid></xrefbib></bibl><bibl id="B114"><title><p>Endogenous and exogenous polyamines in support of tumor growth</p></title><aug><au><snm>Seiler</snm><fnm>N</fnm></au><au><snm>Sarhan</snm><fnm>S</fnm></au><au><snm>Grauffel</snm><fnm>C</fnm></au><au><snm>Jones</snm><fnm>R</fnm></au><au><snm>Knodgen</snm><fnm>B</fnm></au><au><snm>Moulinoux</snm><fnm>JP</fnm></au></aug><source>Cancer Res</source><pubdate>1990</pubdate><volume>50</volume><fpage>5077</fpage><lpage>5083</lpage><xrefbib><pubid idtype="pmpid" link="fulltext">2116224</pubid></xrefbib></bibl><bibl id="B115"><title><p>Polyamine reduced diet (PRD) nutrition therapy in hormone refractory prostate cancer patients</p></title><aug><au><snm>Cipolla</snm><fnm>BG</fnm></au><au><snm>Havouis</snm><fnm>R</fnm></au><au><snm>Moulinoux</snm><fnm>JP</fnm></au></aug><source>Biomed Pharmacother</source><pubdate>2010</pubdate><volume>64</volume><fpage>363</fpage><lpage>368</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1016/j.biopha.2009.09.022</pubid><pubid idtype="pmpid" link="fulltext">20106631</pubid></pubidlist></xrefbib></bibl><bibl id="B116"><title><p>The role of LGL/NK cells in surgery-induced promotion of metastasis and its attenuation by morphine</p></title><aug><au><snm>Page</snm><fnm>GG</fnm></au><au><snm>Ben-Eliyahu</snm><fnm>S</fnm></au><au><snm>Liebeskind</snm><fnm>JC</fnm></au></aug><source>Brain Behav Immun</source><pubdate>1994</pubdate><volume>8</volume><fpage>241</fpage><lpage>250</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1006/brbi.1994.1022</pubid><pubid idtype="pmpid" link="fulltext">7865895</pubid></pubidlist></xrefbib></bibl><bibl id="B117"><title><p>Surgical stress-mediated suppression of murine natural killer cell cytotoxicity</p></title><aug><au><snm>Pollock</snm><fnm>RE</fnm></au><au><snm>Babcock</snm><fnm>GF</fnm></au><au><snm>Romsdahl</snm><fnm>MM</fnm></au><au><snm>Nishioka</snm><fnm>K</fnm></au></aug><source>Cancer Res</source><pubdate>1984</pubdate><volume>44</volume><fpage>3888</fpage><lpage>3891</lpage><xrefbib><pubid idtype="pmpid" link="fulltext">6744305</pubid></xrefbib></bibl><bibl id="B118"><title><p>Enhancing effect of thoracotomy and/or laparotomy on the development of the lung metastases in rats after intravenous inoculation of tumor cells</p></title><aug><au><snm>Hattori</snm><fnm>T</fnm></au><au><snm>Hamai</snm><fnm>Y</fnm></au><au><snm>Harada</snm><fnm>T</fnm></au><au><snm>Ikeda</snm><fnm>H</fnm></au><au><snm>Ikeda</snm><fnm>T</fnm></au></aug><source>Jpn J Surg</source><pubdate>1977</pubdate><volume>7</volume><fpage>263</fpage><lpage>268</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1007/BF02469360</pubid><pubid idtype="pmpid">606897</pubid></pubidlist></xrefbib></bibl><bibl id="B119"><title><p>Human erythrocyte polyamine levels after partial hepatectomy</p></title><aug><au><snm>Tsukamoto</snm><fnm>T</fnm></au><au><snm>Kinoshita</snm><fnm>H</fnm></au><au><snm>Hirohashi</snm><fnm>K</fnm></au><au><snm>Kubo</snm><fnm>S</fnm></au><au><snm>Otani</snm><fnm>S</fnm></au></aug><source>Hepatogastroenterology</source><pubdate>1997</pubdate><volume>44</volume><fpage>744</fpage><lpage>750</lpage><xrefbib><pubid idtype="pmpid">9222683</pubid></xrefbib></bibl><bibl id="B120"><title><p>The potential of a novel polyamine transport inhibitor in cancer chemotherapy</p></title><aug><au><snm>Aziz</snm><fnm>SM</fnm></au><au><snm>Gillespie</snm><fnm>MN</fnm></au><au><snm>Crooks</snm><fnm>PA</fnm></au><au><snm>Tofiq</snm><fnm>SF</fnm></au><au><snm>Tsuboi</snm><fnm>CP</fnm></au><au><snm>Olson</snm><fnm>JW</fnm></au><au><snm>Gosland</snm><fnm>MP</fnm></au></aug><source>J Pharmacol Exp Ther</source><pubdate>1996</pubdate><volume>278</volume><fpage>185</fpage><lpage>192</lpage><xrefbib><pubid idtype="pmpid" link="fulltext">8764350</pubid></xrefbib></bibl><bibl id="B121"><title><p>Combination therapy with 2-difluoromethylornithine and a polyamine transport inhibitor against murine squamous cell carcinoma</p></title><aug><au><snm>Chen</snm><fnm>Y</fnm></au><au><snm>Weeks</snm><fnm>RS</fnm></au><au><snm>Burns</snm><fnm>MR</fnm></au><au><snm>Boorman</snm><fnm>DW</fnm></au><au><snm>Klein-Szanto</snm><fnm>A</fnm></au><au><snm>O&apos;Brien</snm><fnm>TG</fnm></au></aug><source>Int J Cancer</source><pubdate>2006</pubdate><volume>118</volume><fpage>2344</fpage><lpage>2349</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1002/ijc.21621</pubid><pubid idtype="pmpid" link="fulltext">16331620</pubid></pubidlist></xrefbib></bibl></refgrp>
</bm>
</art>